{"content":"<li class=\"n-box-item date-title\" data-end=\"1484197199\" data-start=\"1484110800\" data-txt=\"Sunday, December 22, 2019\">Wednesday, January 11, 2017</li><li class=\"n-box-item sa-box-item\" data-id=\"3234824\" data-ts=\"1484188291\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HSGX\" target=\"_blank\">HSGX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234824-histogenics-joins-party-shares-up-47-after-hours-on-positive-study-data-for-regenerative\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Histogenics joins the party; shares up 47% after hours on positive study data for regenerative cartilage repair NeoCart</a></h4><ul><li>Thinly traded nano cap Histogenics (NASDAQ:<a href='https://seekingalpha.com/symbol/HSGX' title='Histogenics Corporation'>HSGX</a>) rockets&nbsp;<font color='green'>47%</font>&nbsp;after hours on robust volume in response to its <a href=\"https://seekingalpha.com/pr/16711848-histogenics-announces-publication-mri-data-neocart-phase-1-phase-2-clinical-trials-american\" target=\"_blank\">announcement </a>of positive results from Phase 1 &amp; 2 studies assessing lead product candidate NeoCart for the repair of articular cartilage injuries in the knee. The results were just published in the online version of the&nbsp;<em>American Journal of Sports Medicine</em>.</li><li>In a pooled analysis, 29 patients with symptomatic full thickness cartilage lesions in the knee joint were treated with <a href=\"http://www.histogenics.com/products-platform/neocart\" target=\"_blank\">NeoCart</a>, a tissue-engineered implant created with the patient's own cartilage cells. 21 of the patients were evaluable at the final time point of the 60-month follow-up period.</li><li>Analyses by MRI showed significant improvement in cartilage quality from month 3 to 24, with stabilization and maturation from month 24 to 60. NeoCart showed that it was safe and effective through five years of follow-up and that it delivered statistically significant improvements on virtually all pain and functional endpoints as early as month 3 with sustained benefits though month 60.</li><li>NeoCart is currently in Phase 3 development for the first-line treatment of full thickness knee cartilage defects in adults.</li><li>Recent big movers in the biotech nano cap space: (NASDAQ:<a href='https://seekingalpha.com/symbol/GNVC' title='GenVec, Inc.'>GNVC</a>)(SGNL)(ETRM)(NYSEMKT:<a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234824\" data-linked=\"Histogenics joins the party; shares up 47% after hours on positive study data for regenerative cartilage repair NeoCart\" data-tweet=\"$HSGX $OCGN $GNVC - Histogenics joins the party; shares up 47% after hours on positive study data for regenerative cartilage repair NeoCart https://seekingalpha.com/news/3234824-histogenics-joins-party-shares-up-47-after-hours-on-positive-study-data-for-regenerative?source=tweet\" data-url=\"https://seekingalpha.com/news/3234824-histogenics-joins-party-shares-up-47-after-hours-on-positive-study-data-for-regenerative\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234817\" data-ts=\"1484179768\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VECO\" target=\"_blank\">VECO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234817-veeco-boosts-convertible-debt-offering-to-300m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Veeco boosts convertible debt offering to $300M</a></h4><ul>   <li>Veeco Instruments (<a href='https://seekingalpha.com/symbol/VECO' title='Veeco Instruments Inc.'>VECO</a> <font color='red'>-6.2%</font>) has <a href=\"https://seekingalpha.com/pr/16712000-veeco-announces-pricing-upsized-public-offering-convertible-senior-notes-due-2023\" target=\"_blank\">priced an upsized offering</a> of convertible senior debt.</li>    <li>A planned $200M offering was boosted to $300M in 2.7% convertible senior notes due 2023. Underwriters have a 30-day option to buy up to an additional $45M to cover overallotments.</li>    <li>The initial conversion rate of the notes is 24.98 shares of stock per $1,000 principal; that comes to $40.03/share, vs. today's closing price of $27.80.</li>    <li>Net proceeds to Veeco are about $291.5M. The offering is expected to close next Wednesday.</li>    <li>Shares had hit a 52-week high on Dec. 21; shares are <font color='red'>off 8.7%</font> since then.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234817\" data-linked=\"Veeco boosts convertible debt offering to $300M\" data-tweet=\"$VECO - Veeco boosts convertible debt offering to $300M https://seekingalpha.com/news/3234817-veeco-boosts-convertible-debt-offering-to-300m?source=tweet\" data-url=\"https://seekingalpha.com/news/3234817-veeco-boosts-convertible-debt-offering-to-300m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234814\" data-ts=\"1484178461\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KOS\" target=\"_blank\">KOS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234814-kosmos-energyminus-4-on-30m-share-secondary-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kosmos Energy -4% on 30M-share secondary offering</a></h4><ul>     <li>Kosmos Energy (NYSE:<a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy'>KOS</a>) <font color='red'>-3.9%</font> AH after it <a href=\"https://seekingalpha.com/pr/16711926-kosmos-energy-announces-secondary-public-offering-common-shares\" target=\"_blank\">filed to sell 30M common shares</a> for funds affiliated with Warburg Pincus and Blackstone; KOS will receive no proceeds from the sale.</li>     <li>KOS had finished +1% in regular trading after <a href=\"https://seekingalpha.com/filing/3355320\" target=\"_blank\">disclosing</a> that its production estimate for the TEN project remains consistent with forecast of 3-4 cargo liftings in FY 2017.</li>     <li>KOS also anticipates that a facility shutdown of up to 12 weeks may be required during 2017 for its Jubilee field.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234814\" data-linked=\"Kosmos Energy -4% on 30M-share secondary offering\" data-tweet=\"$KOS - Kosmos Energy -4% on 30M-share secondary offering https://seekingalpha.com/news/3234814-kosmos-energyminus-4-on-30m-share-secondary-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3234814-kosmos-energyminus-4-on-30m-share-secondary-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:47 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234812\" data-ts=\"1484176975\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CENX\" target=\"_blank\">CENX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234812-u-s-to-launch-wto-complaint-against-china-over-aluminum\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">U.S. to launch WTO complaint against China over aluminum</a></h4><ul>     <li>Century Aluminum (NASDAQ:<a href='https://seekingalpha.com/symbol/CENX' title='Century Aluminum Company'>CENX</a>) <font color='green'>+1.8%</font> AH following reports that the U.S. will launch a <a href=\"http://www.wsj.com/articles/u-s-expected-to-launch-wto-complaint-against-china-over-aluminum-1484176829\" target=\"_blank\">formal complaint with the WTO</a> claiming that Chinese subsidies to domestic aluminum producers are suppressing global prices of the metal.</li>     <li>The complaint accuses China of funneling artificially cheap loans from state-run banks to Chinese aluminum producers, helping the companies upgrade their facilities and expand production, and says China subsidizes aluminum production by providing producers with cut-rate coal and electricity.</li>     <li>The complaint reportedly may be officially unveiled as soon as tomorrow.</li><li>Other potentially relevant tickers: <a href='https://seekingalpha.com/symbol/AA' title='Alcoa Corporation'>AA</a>, <a href='https://seekingalpha.com/symbol/BLL' title='Ball Corporation'>BLL</a>, <a href='https://seekingalpha.com/symbol/KALU' title='Kaiser Aluminum Corporation'>KALU</a>, <a href='https://seekingalpha.com/symbol/CSTM' title='Constellium Holdco B.V.'>CSTM</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234812\" data-linked=\"U.S. to launch WTO complaint against China over aluminum\" data-tweet=\"$CENX $CENX $AA - U.S. to launch WTO complaint against China over aluminum https://seekingalpha.com/news/3234812-u-s-to-launch-wto-complaint-against-china-over-aluminum?source=tweet\" data-url=\"https://seekingalpha.com/news/3234812-u-s-to-launch-wto-complaint-against-china-over-aluminum\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:22 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234810\" data-ts=\"1484175709\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRWI\" target=\"_blank\">DRWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234810-dragonwave-slides-27-on-disappointing-q3-revenues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DragonWave slides 27% on disappointing Q3 revenues</a></h4><ul>   <li>Packet microwave radio supplier DragonWave (NASDAQ:<a href='https://seekingalpha.com/symbol/DRWI' title='DragonWave Inc.'>DRWI</a>) has taken a tumble after hours, <font color='red'>sliding 27.4% </font>after <a href=\"https://seekingalpha.com/news/3234801-dragonwave-beats-0_12-misses-revenue\" target=\"_blank\">fiscal Q3 revenues</a> were halved and missed expectations.</li>    <li>Revenue from the Nokia channel fell to 22% of total revenue, vs. 24% last quarter. Meanwhile, expenses that remained fairly consistent led to another net loss.</li>    <li>Gross profit dropped to $2.66M from a year-ago $4.93M; before inventory provisions, gross profit was 28.3% vs. last quarter's 31.9%. Opex inched up to $7M.</li>    <li>Revenue breakout: Hardware and other, $7.7M (down 51%); Services, $2.45M (down 54%).</li>    <li>\"Our third quarter revenue performance was disappointing, as operating challenges did not allow us to continue to make the progress that we have been achieving up to this point.\" said CEO Peter Allen. \"With stronger backlog, we remain focused on eliminating these challenges in Q4, and restoring progress on our renewal and restructuring strategy to improve revenue and margin.\"</li>    <li><a href=\"http://investor.dragonwaveinc.com/events.cfm\" target=\"_blank\">Conference call</a> to come tomorrow at 8:30 a.m. ET.</li>    <li><a href=\"https://seekingalpha.com/pr/16711942-dragonwave-reports-third-quarter-fiscal-year-2017-results\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234810\" data-linked=\"DragonWave slides 27% on disappointing Q3 revenues\" data-tweet=\"$DRWI - DragonWave slides 27% on disappointing Q3 revenues https://seekingalpha.com/news/3234810-dragonwave-slides-27-on-disappointing-q3-revenues?source=tweet\" data-url=\"https://seekingalpha.com/news/3234810-dragonwave-slides-27-on-disappointing-q3-revenues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:01 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234806\" data-ts=\"1484174216\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234806-after-hours-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers</a></h4><ul>     <li><b>Top gainers, as of 5.25 p.m.:</b> <a href='https://seekingalpha.com/symbol/HSGX' title='Histogenics Corporation'>HSGX</a> <font color='green'>+29.3%</font>. <a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a> <font color='green'>+19.7%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='green'>+6.8%</font>. <a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a> <font color='green'>+4.0%</font>. <a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a> <font color='green'>+4.0%</font>.</li><li><b>Top losers, as of 5.25p.m.:</b> <a href='https://seekingalpha.com/symbol/KOS' title='Kosmos Energy'>KOS</a> <font color='red'>-5.1%</font>. <a href='https://seekingalpha.com/symbol/AFMD' title='Affimed Therapeutics'>AFMD</a> <font color='red'>-4.4%</font>. <a href='https://seekingalpha.com/symbol/GGB' title='Gerdau S.A.'>GGB</a> <font color='red'>-3.6%</font>. <a href='https://seekingalpha.com/symbol/DB' title='Deutsche Bank AG'>DB</a> <font color='red'>-2.6%</font>. <a href='https://seekingalpha.com/symbol/FTAI' title='Fortress Transportation and Infrastructure Investors LLC'>FTAI</a><font color='red'> -2.65%.</font></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234806\" data-linked=\"After Hours Gainers / Losers\" data-tweet=\"$OCGN $AAOI $ROKA - After Hours Gainers / Losers https://seekingalpha.com/news/3234806-after-hours-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3234806-after-hours-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:36 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234805\" data-ts=\"1484173730\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/FNSR\" target=\"_blank\">FNSR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234805-opticals-up-after-hours-following-strong-preliminary-q4-showing-from-applied-optoelectronics\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Opticals up after hours following strong preliminary Q4 showing from Applied Optoelectronics</a></h4><ul><li><strong>Top extended trade gains</strong> &ndash; Finisar (NASDAQ:<a href='https://seekingalpha.com/symbol/FNSR' title='Finisar Corporation'>FNSR</a>)&nbsp;<font color='green'>+4.61%</font>, Oclaro (NASDAQ:<a href='https://seekingalpha.com/symbol/OCLR' title='Oclaro, Inc.'>OCLR</a>)&nbsp;<font color='green'>+3.92%</font>, Lumentum Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/LITE' title='Lumentum Holdings Inc.'>LITE</a>)&nbsp;<font color='green'>+2.6%</font>, Acacia Communications (NASDAQ:<a href='https://seekingalpha.com/symbol/ACIA' title='Acacia Communications'>ACIA</a>)&nbsp;<font color='green'>+1.6%</font>, Fabrinet (NYSE:<a href='https://seekingalpha.com/symbol/FN' title='Fabrinet'>FN</a>)&nbsp;<font color='green'>+1.15%</font>, NeoPhotonics (NYSE:<a href='https://seekingalpha.com/symbol/NPTN' title='NeoPhotonics Corporation'>NPTN</a>)&nbsp;<font color='green'>+0.54%</font></li><li>Earlier: <a href=\"https://seekingalpha.com/news/3234781-applied-optoelectronics-plus-14_35-percent-preliminary-q4-results-exceed-company-consensus\" target=\"_blank\">Applied Optoelectronics +14.35%; preliminary Q4 results exceed company, consensus expectations</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234805\" data-linked=\"Opticals up after hours following strong preliminary Q4 showing from Applied Optoelectronics\" data-tweet=\"$FNSR $FNSR $OCLR - Opticals up after hours following strong preliminary Q4 showing from Applied Optoelectronics https://seekingalpha.com/news/3234805-opticals-up-after-hours-following-strong-preliminary-q4-showing-from-applied-optoelectronics?source=tweet\" data-url=\"https://seekingalpha.com/news/3234805-opticals-up-after-hours-following-strong-preliminary-q4-showing-from-applied-optoelectronics\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:28 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234800\" data-ts=\"1484171932\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NAK\" target=\"_blank\">NAK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234800-northern-dynasty-mineralsminus-9-on-25m-bought-deal\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Northern Dynasty Minerals -9% on $25M bought deal</a></h4><ul><li>Northern Dynasty Minerals (NYSEMKT:<a href='https://seekingalpha.com/symbol/NAK' title='Northern Dynasty Minerals Ltd'>NAK</a>) <font color='red'>-9%</font>&nbsp;AH after announcing a <a href=\"http://www.marketwired.com/press-release/northern-dynasty-announces-us25-million-bought-deal-tsx-ndm-2187868.htm\" target=\"_blank\">$25M bought deal</a> purchase of 13.5M  common shares at US$1.85 each, with an underwriters option to purchase up to an additional ~2M shares.</li><li>NAK says it plans to use the proceeds to address the EPA's  regulatory action against the Pebble Project; prepare the project for the initiation of federal and state permitting; environmental monitoring,  engineering and environmental studies related to the project; among other corporate purposes.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234800\" data-linked=\"Northern Dynasty Minerals -9% on $25M bought deal\" data-tweet=\"$NAK - Northern Dynasty Minerals -9% on $25M bought deal https://seekingalpha.com/news/3234800-northern-dynasty-mineralsminus-9-on-25m-bought-deal?source=tweet\" data-url=\"https://seekingalpha.com/news/3234800-northern-dynasty-mineralsminus-9-on-25m-bought-deal\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234781\" data-ts=\"1484169927\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAOI\" target=\"_blank\">AAOI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234781-applied-optoelectronicsplus-14_35-preliminary-q4-results-exceed-company-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Applied Optoelectronics +14.35%; preliminary Q4 results exceed company, consensus expectations</a></h4><ul><li><strong><a href=\"https://seekingalpha.com/pr/16711831-applied-optoelectronics-announces-preliminary-fourth-quarter-2016-results\" target=\"_blank\">Preliminary results</a></strong> &ndash; revenue $84.5M-$84.8M (prior outlook $75M-$79M, <a href=\"https://finance.yahoo.com/quote/AAOI/analysts?p=AAOI\" target=\"_blank\">consensus $77.52M</a>), gross margin 37.6%-38% (prior 34%-35.5%), net income after tax $14.2M-$15.2M (prior $8.5M-$9.5M), EPS $0.77-$0.82 (prior $0.46-$0.51, consensus $0.50)</li><li>Applied Optoelectronics (NASDAQ:<a href='https://seekingalpha.com/symbol/AAOI' title='Applied Optoelectronics, Inc.'>AAOI</a>) founder, president and CEO Dr. Thompson Lin: \"Accelerated demand for our market-leading datacenter products and increased capacity fueled our results. Additionally, we continued to drive manufacturing efficiencies, which contributed to a record gross margin. We are excited by the good close to the year and look forward to sharing the additional details of our fourth quarter performance on our conference call in February.\"</li><li>Full posting scheduled for February 23.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234781\" data-linked=\"Applied Optoelectronics +14.35%; preliminary Q4 results exceed company, consensus expectations\" data-tweet=\"$AAOI - Applied Optoelectronics +14.35%; preliminary Q4 results exceed company, consensus expectations https://seekingalpha.com/news/3234781-applied-optoelectronicsplus-14_35-preliminary-q4-results-exceed-company-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3234781-applied-optoelectronicsplus-14_35-preliminary-q4-results-exceed-company-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:25 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234780\" data-ts=\"1484169877\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBH\" target=\"_blank\">KBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234780-kb-homeplus-2_75-after-hours-on-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KB Home +2.75% after hours on earnings beat</a></h4><ul><li>Deliveries of 3,060 homes up 19% Y/Y; ASP of $387.4K up 2%.</li><li>Adjusted housing gross profit margin of 21.6% down 60 basis points from a year ago.</li><li>Net orders of 2,254 up 20% in units; up 27% in value to $856M.</li><li>Backlog value of $1.5B up 19%, and is the highest since 2006.</li><li>For the full year, deliveries of 9,829 homes was up 20%; ASP gained 3% to $363.8K.</li><li><a href=\"http://www.kbhome.com\" target=\"_blank\">Earnings call</a> at 5 ET</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234774-kb-home-beats-0_01-beats-revenue\" target=\"_blank\">KB Home beats by $0.01, beats on revenue</a> (Jan. 11)</li><li><a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a>&nbsp;<font color='green'>+2.75%</font>&nbsp;after hours</li></ul><div class=\"tiny-share-widget\" data-id=\"3234780\" data-linked=\"KB Home +2.75% after hours on earnings beat\" data-tweet=\"$KBH - KB Home +2.75% after hours on earnings beat https://seekingalpha.com/news/3234780-kb-homeplus-2_75-after-hours-on-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3234780-kb-homeplus-2_75-after-hours-on-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234779\" data-ts=\"1484169854\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LTRX\" target=\"_blank\">LTRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234779-lantronix-reports-preliminary-fq2-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Lantronix reports preliminary FQ2 revenue</a></h4><ul>     <li>Lantronix (NASDAQ:<a href='https://seekingalpha.com/symbol/LTRX' title='Lantronix, Inc.'>LTRX</a>) estimates net revenue for the Q217 to be in the range of $10.9 - $11.1M (+14%-16% Y/Y) vs. a consensus of $9.7M.</li>     <li>CEO Jeff Benck: &ldquo;We experienced continued momentum with preliminary results showing year-over-year growth in sales in both our IoT and IT management product lines in the December quarter, I&rsquo;m grateful to our team for finishing the calendar year strong and demonstrating continued operational execution.&rdquo;</li><li>The Company will release FQ2 financial results on Jan. 26, after the market closes.</li><li>Shares&nbsp;<font color='green'>+1.3% AH</font></li><li><a href=\"https://seekingalpha.com/pr/16711849-lantronix-announces-preliminary-revenue-second-quarter-fiscal-2017-ahead-presentation-19th\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234779\" data-linked=\"Lantronix reports preliminary FQ2 revenue\" data-tweet=\"$LTRX - Lantronix reports preliminary FQ2 revenue https://seekingalpha.com/news/3234779-lantronix-reports-preliminary-fq2-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3234779-lantronix-reports-preliminary-fq2-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:24 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234774\" data-ts=\"1484168781\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KBH\" target=\"_blank\">KBH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234774-kb-home-beats-0_01-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">KB Home beats by $0.01, beats on revenue</a></h4><ul><li>KB Home (NYSE:<a href='https://seekingalpha.com/symbol/KBH' title='KB Home'>KBH</a>): Q4 EPS of $0.40 <font color='green'>beats by $0.01</font>.</li><li>Revenue of $1.19B (+20.7% Y/Y) <font color='green'>beats by $40M</font>.</li><li>Shares <font color='green'>+3.25%</font>.</li><li><a href='https://seekingalpha.com/pr/16711839-kb-home-reports-2016-fourth-quarter-full-year-results'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234774\" data-linked=\"KB Home beats by $0.01, beats on revenue\" data-tweet=\"$KBH - KB Home beats by $0.01, beats on revenue https://seekingalpha.com/news/3234774-kb-home-beats-0_01-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3234774-kb-home-beats-0_01-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:06 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234770\" data-ts=\"1484168396\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLF\" target=\"_blank\">CLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234770-rally-in-cliffs-natural-resources-up-15-in-two-days-not-over-analyst-says\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rally in Cliffs Natural Resources, up 15% in two days, not over, analyst says</a></h4><ul>     <li>Cliff Natural Resources (<a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='green'>+4.2%</font>) has soared 15% in two days, following base metals prices higher, is more 75% higher in the past three months, but AlphaShark's Andrew Keene says <a href=\"http://www.cnbc.com/2017/01/11/this-iron-stock-is-red-hot-this-week-and-there-still-may-be-time-to-strike.html\" target=\"_blank\">the rally in the shares is not over</a>.</li>     <li>CLF has been helped by an improving outlook and the expectation that U.S. infrastructure spending will increase, and more recently China's top steelmaking province announced plans <a href=\"https://seekingalpha.com/news/3234480-industrial-metals-stocks-surge-china-cuts-capacity\" target=\"_blank\">earlier this week</a> to cut steel and iron production.</li><li>Alhough CLF still is below its early December highs, it recently passed its 20- and 50-day moving averages, and the stock now is likely to ride its momentum higher, with its recent $11 resistance level soon becoming support, Keene says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234770\" data-linked=\"Rally in Cliffs Natural Resources, up 15% in two days, not over, analyst says\" data-tweet=\"$CLF - Rally in Cliffs Natural Resources, up 15% in two days, not over, analyst says https://seekingalpha.com/news/3234770-rally-in-cliffs-natural-resources-up-15-in-two-days-not-over-analyst-says?source=tweet\" data-url=\"https://seekingalpha.com/news/3234770-rally-in-cliffs-natural-resources-up-15-in-two-days-not-over-analyst-says\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234765\" data-ts=\"1484167587\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VALE\" target=\"_blank\">VALE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234765-brazil-reverses-losses-after-larger-hoped-rate-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brazil reverses losses after larger-than-hoped rate cut</a></h4><ul><li>The central bank slashed its benchmark rate a full 75 basis points to 13% vs. expectations of just a 50 point move.</li><li>Down earlier, the Bovespa is now&nbsp;<font color='green'>higher by 0.5%</font>.</li><li>The iShares MSCI Brazil Index ETF (NYSEARCA:<a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a>) was also lower earlier, but now&nbsp;<font color='green'>up 1.65%</font>.</li><li>Vale (<a href='https://seekingalpha.com/symbol/VALE' title='Vale S.A.'>VALE</a> <font color='green'>+3.5%</font>), Petrobras (<a href='https://seekingalpha.com/symbol/PBR' title='Petrobras - Petroleo Brasileiro S.A.'>PBR</a> <font color='green'>+3.5%</font>), Banco Bradesco (<a href='https://seekingalpha.com/symbol/BBD' title='Banco Bradesco, S.A.'>BBD</a> <font color='green'>+3%</font>), Itau Unibanco (<a href='https://seekingalpha.com/symbol/ITUB' title='Itau Unibanco Holding S.A.'>ITUB</a> <font color='green'>+1.9%</font>), Banco Santander Brasil (<a href='https://seekingalpha.com/symbol/BSBR' title='Banco Santander &#40;Brasil&#41; S.A.'>BSBR</a> <font color='green'>+1.9%</font>), Gol Linhas (<a href='https://seekingalpha.com/symbol/GOL' title='GOL Linhas AÃ©reas Inteligentes S.A.'>GOL</a> <font color='green'>+3.6%</font>)</li><li>ETFs: <a href='https://seekingalpha.com/symbol/EWZ' title='iShares MSCI Brazil Capped ETF'>EWZ</a>, <a href='https://seekingalpha.com/symbol/BRF' title='VanEck Vectors Brazil Small-Cap ETF'>BRF</a>, <a href='https://seekingalpha.com/symbol/BRZU' title='Direxion Daily Brazil Bull 3x Shares ETF'>BRZU</a>, <a href='https://seekingalpha.com/symbol/EWZS' title='iShares MSCI Brazil Small-Cap ETF'>EWZS</a>, <a href='https://seekingalpha.com/symbol/BZQ' title='ProShares UltraShort MSCI Brazil Capped ETF'>BZQ</a>, <a href='https://seekingalpha.com/symbol/BRAQ' title='Global X Brazil Consumer ETF'>BRAQ</a>, <a href='https://seekingalpha.com/symbol/BRAZ' title='Global X Brazil Mid-Cap ETF'>BRAZ</a>, <a href='https://seekingalpha.com/symbol/UBR' title='ProShares Ultra MSCI Brazil Capped ETF'>UBR</a>, <a href='https://seekingalpha.com/symbol/DBBR' title='Deutsche X-trackers MSCI Brazil Hedged Equity ETF'>DBBR</a>, <a href='https://seekingalpha.com/symbol/FBZ' title='First Trust Brazil AlphaDEX ETF'>FBZ</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234765\" data-linked=\"Brazil reverses losses after larger-than-hoped rate cut\" data-tweet=\"$VALE $EWZ $VALE - Brazil reverses losses after larger-than-hoped rate cut https://seekingalpha.com/news/3234765-brazil-reverses-losses-after-larger-hoped-rate-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3234765-brazil-reverses-losses-after-larger-hoped-rate-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>15&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234757\" data-ts=\"1484166198\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NVO\" target=\"_blank\">NVO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234757-abbvie-promises-to-keep-price-hikes-below-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AbbVie promises to keep price hikes below 10%</a></h4><ul><li><a href=\"http://in.reuters.com/article/us-abbvie-pharmaceuticals-prices-idINKBN14V2FK?feedType=RSS&amp;feedName=health&amp;utm_source=Twitter&amp;utm_medium=Social&amp;utm_campaign=Feed%3A+reuters%2FINhealth+%28News+%2F+IN+%2F+Health%29\" target=\"_blank\">The maker of Humira joins</a> Allergan and Novo Nordisk (<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a> <font color='red'>-1.2%</font>) as the first major drugmakers to promise a 10% cap on drug price hikes this year.</li><li>\"There's a strong debate going on right now about pricing,\" AbbVie (<a href='https://seekingalpha.com/symbol/ABBV' title='AbbVie Inc.'>ABBV</a> <font color='red'>-4.5%</font>) CEO Richard Gonzalez tells investors at the JPMorgan Healthcare Conference. \"We need to make sure we are operating in an appropriate way ... and demonstrating the value of the products that we have.\"</li><li>Already under pressure from D.C., pharmaceutical company's are having a rough session after the president-elect took the occasion of his news conference to say they're \"getting away with murder.\"</li><li><a href=\"http://investors.abbvie.com/phoenix.zhtml?c=251551&amp;p=irol-EventDetails&amp;EventId=5245397\" target=\"_blank\">Webcast here</a></li><li>#JPM17</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234752-allergan-ceo-also-twitter-account\" target=\"_blank\">Allergan CEO also has a Twitter account</a> (Jan. 11)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234722-trump-says-slash-drug-prices-federal-bidding\" target=\"_blank\">Trump says he'll slash drug prices through federal bidding</a> (Jan. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234757\" data-linked=\"AbbVie promises to keep price hikes below 10%\" data-tweet=\"$NVO $NVO $ABBV - AbbVie promises to keep price hikes below 10% https://seekingalpha.com/news/3234757-abbvie-promises-to-keep-price-hikes-below-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3234757-abbvie-promises-to-keep-price-hikes-below-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>20&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234755\" data-ts=\"1484165528\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234755-drexel-hamilton-reissues-workday-buy-amid-news-of-deal-wal-mart-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drexel Hamilton reissues Workday at Buy amid news of deal with Wal-Mart Stores</a></h4><ul><li>With Workday management having noted&nbsp;<a href=\"https://seekingalpha.com/article/4027720-workdays-wday-ceo-aneel-bhusri-q3-2017-results-earnings-call-transcript?part=single\" target=\"_blank\">slippage among large deals early in Q4</a>, and shares&nbsp;<font color='red'>declining 20%+</font>&nbsp;since late in November 2016 through late December, <a href=\"http://www.streetinsider.com/Analyst+Comments/Todays+Workday+%28WDAY%29+News+Debunks+Bid+Deal+Concerns%3B+Wal-Mart+Could+Be+Worth+%24200M+in+Annual+Revenue+-+Drexel+Hamilton/12417244.html\" target=\"_blank\">analyst Brian White</a> considers today's <a href=\"https://seekingalpha.com/news/3234737-workday-secures-deal-wal-mart-stores\" target=\"_blank\">deal struck with Wal-Mart Stores</a> to indicate positive financially and represent \"important psychological implications\" for the company.</li><li>Although exact figures and terms of the arrangement aren't known, White estimates inclusion of Wal-Mart Stores' entire 2M+ headcount in the subscription, should that occur, at up to $100M-$200M in annual revenue. However, does note extended time it takes for large deals to factor and expects complete revenue impact to remain unrealized in the immediate term. Such sentiment reflects Workday's own reiteration of prior-issued guidance for Q4 2017 and FY 2018.</li><li>Drexel Hamilton maintains Workday (<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a> <font color='green'>+8.1%</font>) at Buy and $104 target (current price $80.36).</li><li>Earlier:&nbsp;<a href=\"https://seekingalpha.com/news/3234704-workday-trading-halted-pending-news-release\" target=\"_blank\">Workday trading halted for pending news release</a>&nbsp;/&nbsp;<a href=\"https://seekingalpha.com/news/3234678-workday-plus-7_2-percent-william-blair-indicates-contract-company-employing-2m\" target=\"_blank\">Workday +7.2%; William Blair indicates contract with company employing 2M+</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234755\" data-linked=\"Drexel Hamilton reissues Workday at Buy amid news of deal with Wal-Mart Stores\" data-tweet=\"$WDAY - Drexel Hamilton reissues Workday at Buy amid news of deal with Wal-Mart Stores https://seekingalpha.com/news/3234755-drexel-hamilton-reissues-workday-buy-amid-news-of-deal-wal-mart-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3234755-drexel-hamilton-reissues-workday-buy-amid-news-of-deal-wal-mart-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:12 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234754\" data-ts=\"1484165518\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EV\" target=\"_blank\">EV</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234754-eaton-vance-adds-little-on-added-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eaton Vance adds a little on added buyback</a></h4><ul><li>Alongside declaration of its $0.28 quarterly dividend, Eaton Vance (NYSE:<a href='https://seekingalpha.com/symbol/EV' title='Eaton Vance Corporation'>EV</a>) announces authorization <a href=\"https://seekingalpha.com/pr/16711757-eaton-vance-declares-quarterly-dividend-authorizes-repurchase-8-million-shares\" target=\"_blank\">to buy back up to</a> 8M shares. This replaces last year's plan under which the company repurchased 6M shares.</li><li>EV's float is about 114M shares.</li><li>Flat ahead of the news, the stock is now&nbsp;<font color='green'>higher by 0.65%</font>&nbsp;on the session.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234754\" data-linked=\"Eaton Vance adds a little on added buyback\" data-tweet=\"$EV - Eaton Vance adds a little on added buyback https://seekingalpha.com/news/3234754-eaton-vance-adds-little-on-added-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3234754-eaton-vance-adds-little-on-added-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:11 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234756\" data-ts=\"1484165333\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XTNT\" target=\"_blank\">XTNT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234756-xtant-medical-reports-preliminary-q4-and-fy16-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xtant Medical reports preliminary Q4 and FY16 results</a></h4><ul>     <li>Xtant Medical Holdings (NYSEMKT:<a href='https://seekingalpha.com/symbol/XTNT' title='Xtant Medical Holdings, Inc.'>XTNT</a>) expects Q4 revenue to be at least $24.5M (+10% Y/Y) vs. a consensus of $24.3M. Adjusted EBITDA is estimated to be at least $1.25M vs. a loss of $0.35M in the Q415.</li>     <li>Full year 2016, the Company has estimated that its sales will be at least $90.0M which represents 4.1% year on year growth. Adjusted EBITDA is estimated to be at least $2.2M vs. a loss of $335 for the FY15.</li>     <li>Reiterated 2017 Revenue guidance of between $98 - $102M.</li><li>Reiterated 2017 Adjusted EBITDA guidance of between $7.7 - $9.2M.</li><li>Shares&nbsp;<font color='green'>+17%</font></li><li><a href=\"https://seekingalpha.com/pr/16711383-xtnt-announces-preliminary-fourth-quarter-full-year-2016-revenue-and-adjusted-ebitda\" target=\"_blank\">Press Release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234756\" data-linked=\"Xtant Medical reports preliminary Q4 and FY16 results\" data-tweet=\"$XTNT - Xtant Medical reports preliminary Q4 and FY16 results https://seekingalpha.com/news/3234756-xtant-medical-reports-preliminary-q4-and-fy16-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3234756-xtant-medical-reports-preliminary-q4-and-fy16-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:08 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234752\" data-ts=\"1484165050\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AGN\" target=\"_blank\">AGN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234752-allergan-ceo-also-twitter-account\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Allergan CEO also has a Twitter account</a></h4><ul><li>\"Ultimately, we want the same thing as the president-elect,\"<a href=\"https://twitter.com/brentlsaunders/status/819253851853234177\" target=\"_blank\"> tweets</a> Allergan (<a href='https://seekingalpha.com/symbol/AGN' title='Allergan plc'>AGN</a> <font color='red'>-2.2%</font>) CEO Brent Saunders. \"1) Supportive environment for innovation 2) Patient access and affordability for healthcare 3) Smart people with good U.S. jobs.\"</li><li>Also on the move post-Trump: Mylan (<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a> <font color='red'>-4.2%</font>), Perrigo (<a href='https://seekingalpha.com/symbol/PRGO' title='Perrigo Company'>PRGO</a> <font color='red'>-7.5%</font>), Valeant (VRX <font color='red'>-5.5%</font>), Bristol-Myers Squibb (<a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-5%</font>),&nbsp;Mallinckrodt (<a href='https://seekingalpha.com/symbol/MNK' title='Mallinckrodt PLC'>MNK</a> <font color='red'>-6.7%</font>), BioMarin (<a href='https://seekingalpha.com/symbol/BMRN' title='BioMarin Pharmaceutical Inc.'>BMRN</a> <font color='red'>-4.6%</font>)</li><li>The <a href='https://seekingalpha.com/symbol/XLV' title='Health Care Select Sect SPDR ETF'>XLV</a> is&nbsp;<font color='red'>lower by 1.1%</font>.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234705-drug-makers-biotechs-retreat-trumps-negative-comments\" target=\"_blank\">Drug makers and biotechs in retreat on Trump's negative comments</a> (Jan. 11)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234752\" data-linked=\"Allergan CEO also has a Twitter account\" data-tweet=\"$AGN $AGN $MYL - Allergan CEO also has a Twitter account https://seekingalpha.com/news/3234752-allergan-ceo-also-twitter-account?source=tweet\" data-url=\"https://seekingalpha.com/news/3234752-allergan-ceo-also-twitter-account\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>81&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234750\" data-ts=\"1484164805\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234750-technology-top-gainers-losers-of-3-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top Gainers / Losers as of 3:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/SMIT' title='Schmitt Industries, Inc.'>SMIT</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/MVIS' title='Microvision, Inc.'>MVIS</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/HMNY' title='Helios and Matheson Analytics, Inc.'>HMNY</a> <font color='green'>+10%</font>. <a href='https://seekingalpha.com/symbol/INSG' title='Inseego Corp.'>INSG</a> <font color='green'>+10%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/MDSY' title='ModSys International Ltd.'>OTC:MDSY</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/NMRX' title='Numerex Corp.'>NMRX</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/SCON' title='Superconductor Technologies Inc.'>SCON</a> <font color='red'>-7%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234750\" data-linked=\"Technology - Top Gainers / Losers as of 3:00 pm\" data-tweet=\"$ENPH $SMIT $MVIS - Technology - Top Gainers / Losers as of 3:00 pm https://seekingalpha.com/news/3234750-technology-top-gainers-losers-of-3-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3234750-technology-top-gainers-losers-of-3-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:00 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234746\" data-ts=\"1484163380\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RIG\" target=\"_blank\">RIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234746-ge-transocean-sign-180m-service-agreement-covering-drilling-rigs\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">GE, Transocean sign $180M service agreement covering drilling rigs</a></h4><ul>     <li>Transocean (<a href='https://seekingalpha.com/symbol/RIG' title='Transocean Ltd.'>RIG</a> <font color='green'>+4.2%</font>) enjoys strong gains after GE Oil &amp; Gas (<a href='https://seekingalpha.com/symbol/GE' title='General Electric'>GE</a> <font color='green'>+0.1%</font>) announces a <a href=\"http://www.epmag.com/ge-transocean-sign-performance-based-service-agreement-1458316\" target=\"_blank\">new contractual service agreement</a>, valued at ~$180M, that will attempt to further maximize productivity and lower operating costs for RIG.</li>     <li>GE says it will provide condition-based monitoring and maintenance services for pressure control equipment on seven of RIG&rsquo;s rigs over the next 10-12 years, in a change from event and calendar-based maintenance.</li>     <li>GE says the agreement builds on its new business model based on service to address the industry shift toward maximizing productivity and cutting operating costs.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234746\" data-linked=\"GE, Transocean sign $180M service agreement covering drilling rigs\" data-tweet=\"$RIG $RIG $GE - GE, Transocean sign $180M service agreement covering drilling rigs https://seekingalpha.com/news/3234746-ge-transocean-sign-180m-service-agreement-covering-drilling-rigs?source=tweet\" data-url=\"https://seekingalpha.com/news/3234746-ge-transocean-sign-180m-service-agreement-covering-drilling-rigs\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:36 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234743\" data-ts=\"1484162638\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234743-energy-materials-top-5-gainers-losers-of-2-20-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials - Top 5 Gainers / Losers as of 2:20 pm</a></h4><ul> <li><b>Gainers:</b> URRE <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp'>UEC</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/USEG' title='U.S. Energy Corp.'>USEG</a> <font color='green'>+10%</font>. SGY <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/ATW' title='Atwood Oceanics Inc.'>ATW</a> <font color='green'>+7%</font>.</li> <li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/CGG-OLD' title='CGG'>CGG-OLD</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3234743\" data-linked=\"Energy/Materials - Top 5 Gainers / Losers as of 2:20 pm\" data-tweet=\"$WWR $UEC $USEG - Energy/Materials - Top 5 Gainers / Losers as of 2:20 pm https://seekingalpha.com/news/3234743-energy-materials-top-5-gainers-losers-of-2-20-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3234743-energy-materials-top-5-gainers-losers-of-2-20-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:23 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234740\" data-ts=\"1484162137\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234740-brean-boosts-lions-gate-price-target-after-investor-day\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brean boosts Lions Gate price target after investor day</a></h4><ul>   <li>After Lions Gate's (LGF.A <font color='green'>+2%</font>) first investor day, Brean Capital has bumped its price target a bit following an upbeat presentation.</li>    <li>The firm's Alan Gould raised his target to $32 from $30, implying 14% upside.</li>    <li>The company operates in the \"<a href=\"http://www.benzinga.com/analyst-ratings/analyst-color/17/01/8893823/lions-gate-operates-in-the-sweet-spot-of-content-provide\" target=\"_blank\">sweet spot of the media business</a> focused on content creation\" as well as boasting a strong track record with acquisitions -- particularly the acquisition of Starz, which Gould says is highly accretive and diversifies the business: &ldquo;We anticipate rapid de-leveraging resulting from the Starz acquisition.\"</li>    <li>With his estimate for free cash flow at $455M (about $2/share) for fiscal 2018, blended shares are trading for less than 13 times FCF/share, Gould says.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234740\" data-linked=\"Brean boosts Lions Gate price target after investor day\" data-tweet=\"Brean boosts Lions Gate price target after investor day https://seekingalpha.com/news/3234740-brean-boosts-lions-gate-price-target-after-investor-day?source=tweet\" data-url=\"https://seekingalpha.com/news/3234740-brean-boosts-lions-gate-price-target-after-investor-day\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:15 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234737\" data-ts=\"1484160576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234737-workday-secures-deal-wal-mart-stores\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday secures deal with Wal-Mart Stores</a></h4><ul><li>Wal-Mart Stores&nbsp;<a href=\"https://seekingalpha.com/filing/3354879\" target=\"_blank\">has purchased subscription</a> to Workday Human Capital Management, Recruiting, Learning and Planning, representing what is considered a deal involving a substantially greater number of employees than any of Workday's existing contracts.</li><li>Company outlook for both Q4 2017 and FY 2018 unchanged.</li><li>Workday (NYSE:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a>)&nbsp;<font color='green'>+7.38%</font>.</li><li>Earlier:&nbsp;<a href=\"https://seekingalpha.com/news/3234704-workday-trading-halted-pending-news-release\" target=\"_blank\">Workday trading halted for pending news release</a>&nbsp;/&nbsp;<a href=\"https://seekingalpha.com/news/3234678-workday-plus-7_2-percent-william-blair-indicates-contract-company-employing-2m\" target=\"_blank\">Workday +7.2%; William Blair indicates contract with company employing 2M+</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234737\" data-linked=\"Workday secures deal with Wal-Mart Stores\" data-tweet=\"$WDAY - Workday secures deal with Wal-Mart Stores https://seekingalpha.com/news/3234737-workday-secures-deal-wal-mart-stores?source=tweet\" data-url=\"https://seekingalpha.com/news/3234737-workday-secures-deal-wal-mart-stores\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:49 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234730\" data-ts=\"1484158236\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234730-financials-top-5-gainers-losers-of-1-10-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Financials - Top 5 Gainers / Losers as of 1:10 PM</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/ATLC' title='Atlanticus Holdings Corp.'>ATLC</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/SIEB' title='Siebert Financial Corp.'>SIEB</a> <font color='green'>+5%</font>. <a href='https://seekingalpha.com/symbol/MSB' title='Mesabi Trust'>MSB</a> <font color='green'>+5%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/BRG' title='Bluerock Residential Growth REIT, Inc.'>BRG</a> <font color='red'>-5%</font>. WMIH <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234730\" data-linked=\"Financials - Top 5 Gainers / Losers as of 1:10 PM\" data-tweet=\"$ATLC $SIEB $MSB - Financials - Top 5 Gainers / Losers as of 1:10 PM https://seekingalpha.com/news/3234730-financials-top-5-gainers-losers-of-1-10-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3234730-financials-top-5-gainers-losers-of-1-10-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:10 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234724\" data-ts=\"1484157167\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PSX\" target=\"_blank\">PSX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234724-crude-oilplus-3-data-shows-refiners-processed-record-volumes\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude oil +3% as data shows refiners processed record volumes</a></h4><ul>     <li><a href=\"http://www.wsj.com/articles/oil-prices-nudge-up-after-recent-slide-1484133177\" target=\"_blank\">U.S. crude oil climbs 3.2%</a> to $52.45/bbl after <a href=\"https://seekingalpha.com/news/3234679-crude-futures-give-gains-post-inventory-data\" target=\"_blank\">EIA data</a> showed that refiners processed a record amount of crude and that supplies fell at the Cushing, Okla., storage hub.</li>     <li>U.S. refiners churned 17.1M bbl/day of crude into fuel last week, the highest weekly figure going back to 1982, while Cushing stockpiles, which have been rising in recent weeks, fell by 579K barrels.</li>     <li>Prices recovered after initially falling in reaction to a higher than expected rise in total crude oil inventories to 4.1M barrels, and U.S. production jumped to more than 8.9M bbl/day during the week, the highest read since April.</li>     <li>But analysts say the stockpile gains largely were driven by an increase in oil imports, which rose to their highest level since 2012 as shipments of crude that were delayed at the end of last year for tax purposes are starting to appear.</li><li>Refiners are higher: <a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='green'>+1.5%</font>, <a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='green'>+0.8%</font>, <a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='green'>+1.9%</font>, TSO <font color='green'>+1.1%</font>, <a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='green'>+2.1</font>%, <a href='https://seekingalpha.com/symbol/WNR' title='Western Refining, Inc.'>WNR</a> <font color='green'>+0.9%</font>, <a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='green'>+0.3%</font>, <a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='green'>+0.7%</font>, <a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a> <font color='green'>+0.4%</font>.</li><li>ETFs: <a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>, <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DBO' title='Invesco DB Oil ETF'>DBO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>, <a href='https://seekingalpha.com/symbol/UGA' title='The United States Gasoline ETF, LP'>UGA</a>, <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>, <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>, <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>, <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234724\" data-linked=\"Crude oil +3% as data shows refiners processed record volumes\" data-tweet=\"$PSX $PSX $VLO - Crude oil +3% as data shows refiners processed record volumes https://seekingalpha.com/news/3234724-crude-oilplus-3-data-shows-refiners-processed-record-volumes?source=tweet\" data-url=\"https://seekingalpha.com/news/3234724-crude-oilplus-3-data-shows-refiners-processed-record-volumes\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>27&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234722\" data-ts=\"1484156576\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234722-trump-says-slash-drug-prices-through-federal-bidding\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Trump says he&#39;ll slash drug prices through federal bidding</a></h4><ul><li>Adding more color to an earlier post, President-elect Trump said in his first press conference that:</li><li>&ldquo;We have to get our drug industry coming back. Our drug  industry has been disastrous. They&rsquo;re leaving left and right. They  supply our drugs but they don&rsquo;t make them here, to a large extent. And  the other thing we have to do is create new bidding procedures with the  drug industry. They&rsquo;re getting away with murder. Pharma has a lot of  lobbyists and a lot of power and there's very little bidding on drugs. We&rsquo;re the largest buyer of drugs in the world, and yet we don&rsquo;t bid  properly. We&rsquo;re going to start bidding. We&rsquo;re going to save billions of  dollars over a period of time.&rdquo;</li><li>During the campaign, Mr. Trump commented that Medicare should have the right to negotiate drug prices, an issue the industry aggressively lobbied against.</li><li>With the tone of his rhetoric, pharma and biotech firms will never have a dull moment for the foreseeable future.</li><li>Source:&nbsp;<a href=\"https://endpts.com/breaking-donald-trump-promises-to-slash-drug-prices-by-billions-promises-aggressive-federal-bidding-process/\" target=\"_blank\">John Carroll</a></li><li>Representative tickers: (<a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a> <font color='red'>-7.5%</font>)(<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='red'>-3.7%</font>)(<a href='https://seekingalpha.com/symbol/PJP' title='PowerShares Dynamic Pharmaceuticals Portfolio ETF'>PJP</a> <font color='red'>-2.7%</font>)(<a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a> <font color='red'>-3.8%</font>)(<a href='https://seekingalpha.com/symbol/PPH' title='VanEck Vectors Pharmaceutical ETF'>PPH</a> <font color='red'>-2.5%</font>)(<a href='https://seekingalpha.com/symbol/PILL' title='Direxion Daily Pharmaceutical & Medical Bull 2X Shares ETF'>PILL</a> <font color='red'>-7.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234722\" data-linked=\"Trump says he&#39;ll slash drug prices through federal bidding\" data-tweet=\"$BIB $IBB $PJP - Trump says he&#39;ll slash drug prices through federal bidding https://seekingalpha.com/news/3234722-trump-says-slash-drug-prices-through-federal-bidding?source=tweet\" data-url=\"https://seekingalpha.com/news/3234722-trump-says-slash-drug-prices-through-federal-bidding\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:42 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>95&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234721\" data-ts=\"1484156410\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234721-midday-gainers-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Midday Gainers / Losers</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/MYOS' title='MYOS RENS Technology'>MYOS</a> <font color='green'>+85%</font>. URRE <font color='green'>+49%</font>. <a href='https://seekingalpha.com/symbol/DSCI' title='Derma Sciences Inc.'>DSCI</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+26%</font>. <a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a> <font color='green'>+24%</font>. <a href='https://seekingalpha.com/symbol/KRNT' title='Kornit Digital'>KRNT</a> <font color='green'>+23%</font>. <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/USEG' title='U.S. Energy Corp.'>USEG</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp'>UEC</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/CIDM' title='Cinedigm Corp.'>CIDM</a> <font color='green'>+15%</font>.</li><li><b>Losers:</b> SGNL <font color='red'>-40%</font>. ETRM <font color='red'>-40%</font>. <a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/GNVC' title='GenVec, Inc.'>GNVC</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/CUR' title='Neuralstem, Inc.'>CUR</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/NVDQ' title='Novadaq Technologies Inc.'>NVDQ</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/MBRX' title='Moleculin Biotech, Inc.'>MBRX</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='red'>-13%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234721\" data-linked=\"Midday Gainers / Losers\" data-tweet=\"$MYOS $WWR $DSCI - Midday Gainers / Losers https://seekingalpha.com/news/3234721-midday-gainers-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3234721-midday-gainers-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234717\" data-ts=\"1484154429\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NXST\" target=\"_blank\">NXST</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234717-nexstar-media-general-sharply-higher-fcc-approves-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Nexstar, Media General sharply higher as FCC approves merger</a></h4><ul>   <li>Nexstar Broadcasting (NASDAQ:<a href='https://seekingalpha.com/symbol/NXST' title='Nexstar Media Group, Inc.'>NXST</a>) has <font color='green'>jumped 5.3%</font> and Media General (NYSE:<a href='https://seekingalpha.com/symbol/MEG' title='Media General'>MEG</a>) has <font color='green'>zipped up 2.8%</font> as the FCC has <a href=\"http://www.broadcastingcable.com/news/washington/fcc-okays-nexstar-media-general-merger/162370\" target=\"_blank\">given its OK to the two companies' merger</a>.</li>    <li>That comes after the agency waived its own rule preventing a decision on the deal during the broadcast incentive spectrum auction.</li>    <li>The companies had submitted to spin-offs and conditions to make the merger comply with ownership rules.</li>    <li>The approval comes over objections to the deal filed by the American Cable Association, Cox, and Dish Network.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3212869-fcc-tied-auction-nexstars-sook-eager-wrap-media-general-deal\" target=\"_blank\">With FCC tied up in auction, Nexstar's Sook eager to wrap Media General deal</a> (Oct. 06 2016)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3234717\" data-linked=\"Nexstar, Media General sharply higher as FCC approves merger\" data-tweet=\"$NXST $NXST $MEG - Nexstar, Media General sharply higher as FCC approves merger https://seekingalpha.com/news/3234717-nexstar-media-general-sharply-higher-fcc-approves-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3234717-nexstar-media-general-sharply-higher-fcc-approves-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:07 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234713\" data-ts=\"1484154257\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234713-consumer-top-gainers-losers-of-12-00-pm\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Consumer - Top Gainers / Losers as of 12:00 pm</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/VRTV' title='Veritiv'>VRTV</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/ETH' title='Ethan Allen Interiors Inc.'>ETH</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/SNAK' title='Inventure Foods, Inc.'>SNAK</a> <font color='red'>-8%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234713\" data-linked=\"Consumer - Top Gainers / Losers as of 12:00 pm\" data-tweet=\"$VRTV $ETH $SNAK - Consumer - Top Gainers / Losers as of 12:00 pm https://seekingalpha.com/news/3234713-consumer-top-gainers-losers-of-12-00-pm?source=tweet\" data-url=\"https://seekingalpha.com/news/3234713-consumer-top-gainers-losers-of-12-00-pm\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:04 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234710\" data-ts=\"1484153796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ISRG\" target=\"_blank\">ISRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234710-intuitive-surgical-sees-2016-revenues-in-line-consensus-view-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Intuitive Surgical sees 2016 revenues in line with consensus view; shares ahead 2%</a></h4><ul><li>On a <a href=\"https://seekingalpha.com/pr/16711360-intuitive-surgical-announces-preliminary-fourth-quarter-full-year-2016-results\" target=\"_blank\">preliminary basis</a>, Intuitive Surgical (<a href='https://seekingalpha.com/symbol/ISRG' title='Intuitive Surgical, Inc.'>ISRG</a> <font color='green'>+1.6%</font>) sees Q4 and full-year revenues of $757M (+12%) and $2.7B (+13%), respectively. Q4's top line tops consensus of $740M while the annual figure is in line.</li><li>Q4 instrument and accessory sales are expected to be $386M up 19% yoy. For the year, sales should be $1.4B (+17%).</li><li>Number of surgical procedures performed with the da Vinci System in 2016: 753K (+15%).</li><li>The company is scheduled to deliver a corporate overview tomorrow, January 12 at 9:00 am PT at JPM17. Final Q4 and 2016 results will be released on January 24.</li><li>$JPM17</li></ul><div class=\"tiny-share-widget\" data-id=\"3234710\" data-linked=\"Intuitive Surgical sees 2016 revenues in line with consensus view; shares ahead 2%\" data-tweet=\"$ISRG - Intuitive Surgical sees 2016 revenues in line with consensus view; shares ahead 2% https://seekingalpha.com/news/3234710-intuitive-surgical-sees-2016-revenues-in-line-consensus-view-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3234710-intuitive-surgical-sees-2016-revenues-in-line-consensus-view-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:56 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234709\" data-ts=\"1484153430\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IMMR\" target=\"_blank\">IMMR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234709-immersionminus-7_42-apple-granted-inter-parties-review-of-unpatentability-of-certain\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Immersion -7.42%; Apple granted inter parties review of unpatentability of certain Immersion claims [updated]</a></h4><ul><li>Apple has filed for review of Immersion claims 1-3, 5, 7, 9-13, 15, 17, 19-23, 25 and 26 of of U.S. Patent&nbsp;No. 8,773,356 B2 (Ex. 1001, &ldquo;the &rsquo;356 patent&rdquo;) and <a href=\"https://www.scribd.com/document/336284734/Apple-IPR-instituted-on-Immersion-356-patent\" target=\"_blank\">has been granted</a> the request given Apple's \"reasonable likelihood of&nbsp;prevailing in showing the unpatentability\" of those claims.</li><li>Immersion (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMR' title='Immersion Corporation'>IMMR</a>)&nbsp;shares to $10.23 at midday.</li><li><strong>Update</strong>: Apple's review requests partially granted regarding challenged claims of <a href=\"https://www.scribd.com/document/336297067/Apple-IPR-instituted-against-10-of-21-Immersion-571-patent-claims\" target=\"_blank\">U.S. Patent No. 8,659,571 B2 (Ex. 1001, &ldquo;the &rsquo;571 patent&rdquo;)</a> and denied regarding challenged claims of&nbsp;<a href=\"https://www.scribd.com/document/336305896/Apple-IPR-vs-Immersion-051-patent-claims-denied\" target=\"_blank\">U.S. Patent No. 8,619,051 B2 (Ex. 1001, &ldquo;the &rsquo;051 patent&rdquo;)</a>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234709\" data-linked=\"Immersion -7.42%; Apple granted inter parties review of unpatentability of certain Immersion claims [updated]\" data-tweet=\"$IMMR - Immersion -7.42%; Apple granted inter parties review of unpatentability of certain Immersion claims [updated] https://seekingalpha.com/news/3234709-immersionminus-7_42-apple-granted-inter-parties-review-of-unpatentability-of-certain?source=tweet\" data-url=\"https://seekingalpha.com/news/3234709-immersionminus-7_42-apple-granted-inter-parties-review-of-unpatentability-of-certain\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234714\" data-ts=\"1484152382\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OMTL\" target=\"_blank\">OMTL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234714-upland-software-announces-acquisition-updates-guidance-and-raises-adjusted-ebtda-margin\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Upland Software announces acquisition; Updates guidance and raises adjusted EBTDA margin target</a></h4><ul>     <li>Upland Software (UPLD&nbsp;<font color='green'>+2.5%</font>) <a href=\"https://seekingalpha.com/pr/16710960-upland-software-announces-acquisition-provides-positive-guidance-update-raises-adjusted\" target=\"_blank\">announced</a> that it has acquired Omtool (<a href='https://seekingalpha.com/symbol/OMTL' title='Omtool, Ltd.'>OTCPK:OMTL</a>), an award-winning enterprise document capture, fax, and workflow solution for $19.2M (net of cash acquired). The acquisition was within company's target range of 5-8x pro forma Adjusted EBITDA and likely to generate ~11.0M in revenue in 2017. The transaction will be immediately accretive to Upland's Adjusted EBITDA &nbsp;per share.</li>     <li><strong>Business outlook</strong>: Upland expects total revenue and Adjusted EBITDA for Q4 to be at the upper end of previously-announced guidance ranges.</li>     <li>Upland expects Q1 revenue to be in the range of $20.0 -$20.8M including recurring revenue in the range of $17.5 - $18.1M (+17% Y/Y). Adjusted EBITDA is expected to be in the range of $5.0 - $5.5M, for an Adjusted EBITDA margin of 26% at the mid-point, representing growth of 162% (Y/Y).</li>     <li>Chairman and CEO, Jack McDonald: \"Q4 came in strong with continued success in expanding our customer relationships allowing us to affirm our healthy Q4 outlook and to provide record Q1 guidance that reflects both the Omtool acquisition and the continued growth in our core business, Finally, we are raising our long term Adjusted EBITDA margin target to 35% to reflect the increased customer loyalty and operating efficiency we are seeing as we scale.\"</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234714\" data-linked=\"Upland Software announces acquisition; Updates guidance and raises adjusted EBTDA margin target\" data-tweet=\"$OMTL - Upland Software announces acquisition; Updates guidance and raises adjusted EBTDA margin target https://seekingalpha.com/news/3234714-upland-software-announces-acquisition-updates-guidance-and-raises-adjusted-ebtda-margin?source=tweet\" data-url=\"https://seekingalpha.com/news/3234714-upland-software-announces-acquisition-updates-guidance-and-raises-adjusted-ebtda-margin\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:33 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234705\" data-ts=\"1484152103\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234705-drug-makers-and-biotechs-in-retreat-on-trumps-negative-comments\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Drug makers and biotechs in retreat on Trump&#39;s negative comments</a></h4><ul><li>The rally in pharma and biotech stocks has fizzled on the heels of President-elect Trump's comments this morning saying the drug industry is \"getting away with murder\" (regarding pricing) and that \"we need new bidding procedures\" for the drug industry.</li><li>ETFs: (<a href='https://seekingalpha.com/symbol/BIB' title='ProShares Ultra Nasdaq Biotechnology ETF'>BIB</a> <font color='red'>-5.4%</font>) (<a href='https://seekingalpha.com/symbol/GRX' title='The Gabelli Healthcare & Wellness Rx Trust'>GRX</a> <font color='green'>+0.2%</font>)(<a href='https://seekingalpha.com/symbol/BIS' title='ProShares UltraShort Nasdaq Biotechnology ETF'>BIS</a> <font color='green'>+6.6%</font>)(<a href='https://seekingalpha.com/symbol/IRY' title='SPDR S&P International Health Care Sector ETF'>IRY</a> <font color='red'>-0.7%</font>)(<a href='https://seekingalpha.com/symbol/IXJ' title='iShares Global Healthcare ETF'>IXJ</a> <font color='red'>-1.2%</font>)(<a href='https://seekingalpha.com/symbol/BME' title='BlackRock Health Sciences Trust'>BME</a> <font color='green'>+0.9%</font>)(<a href='https://seekingalpha.com/symbol/CNCR' title='Loncar Cancer Immunotherapy ETF'>CNCR</a>)(<a href='https://seekingalpha.com/symbol/THW' title='Tekla World Healthcare Fund'>THW</a>)(<a href='https://seekingalpha.com/symbol/ARKG' title='ARK Genomic Revolution Multi-Sector ETF'>ARKG</a>)(<a href='https://seekingalpha.com/symbol/GNRX' title='VanEck Vectors Generic Drugs ETF'>GNRX</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/IBB' title='iShares Nasdaq Biotechnology ETF'>IBB</a> <font color='red'>-3.4%</font>)(<a href='https://seekingalpha.com/symbol/PJP' title='PowerShares Dynamic Pharmaceuticals Portfolio ETF'>PJP</a> <font color='red'>-2.3%</font>)(<a href='https://seekingalpha.com/symbol/IHE' title='iShares U.S. Pharmaceuticals ETF'>IHE</a> <font color='red'>-0.3%</font>)(<a href='https://seekingalpha.com/symbol/XPH' title='SPDR S&P Pharmaceuticals ETF'>XPH</a> <font color='red'>-3%</font>)(<a href='https://seekingalpha.com/symbol/PPH' title='VanEck Vectors Pharmaceutical ETF'>PPH</a> <font color='red'>-2%</font>)(<a href='https://seekingalpha.com/symbol/GNRX' title='VanEck Vectors Generic Drugs ETF'>GNRX</a> <font color='green'>+0.4%</font>)(<a href='https://seekingalpha.com/symbol/PILL' title='Direxion Daily Pharmaceutical & Medical Bull 2X Shares ETF'>PILL</a> <font color='red'>-7.8%</font>)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234705\" data-linked=\"Drug makers and biotechs in retreat on Trump&#39;s negative comments\" data-tweet=\"$BIB $GRX $BIS - Drug makers and biotechs in retreat on Trump&#39;s negative comments https://seekingalpha.com/news/3234705-drug-makers-and-biotechs-in-retreat-on-trumps-negative-comments?source=tweet\" data-url=\"https://seekingalpha.com/news/3234705-drug-makers-and-biotechs-in-retreat-on-trumps-negative-comments\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>13&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234704\" data-ts=\"1484152040\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234704-workday-trading-halted-for-pending-news-release\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday trading halted for pending news release</a></h4><ul><li>Workday (NYSE:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a>) shares are&nbsp;<font color='green'>+8.53%</font>&nbsp;for the session on 3.04M share volume over a 2.91M average. [<a href=\"https://www.nasdaqtrader.com/trader.aspx?id=TradeHalts\" target=\"_blank\">trading halt</a>]</li><li>Earlier: <a href=\"https://seekingalpha.com/news/3234678-workday-plus-7_2-percent-william-blair-indicates-contract-company-employing-2m\" target=\"_blank\">Workday +7.2%; William Blair indicates contract with company employing 2M+</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234704\" data-linked=\"Workday trading halted for pending news release\" data-tweet=\"$WDAY - Workday trading halted for pending news release https://seekingalpha.com/news/3234704-workday-trading-halted-for-pending-news-release?source=tweet\" data-url=\"https://seekingalpha.com/news/3234704-workday-trading-halted-for-pending-news-release\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:27 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234701\" data-ts=\"1484151641\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SYK\" target=\"_blank\">SYK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234701-stryker-up-2-on-preliminary-q4-and-full-year-results-are-inline-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Stryker up 2% on preliminary Q4 and full-year results that are inline with consensus</a></h4><ul><li>Stryker (<a href='https://seekingalpha.com/symbol/SYK' title='Stryker Corporation'>SYK</a> <font color='green'>+1.6%</font>) perks up modestly higher volume after yesterday's release of <a href=\"https://seekingalpha.com/filing/3353758\" target=\"_blank\">preliminary results</a> for Q4 and 2016 that will meet consensus views.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234526-stryker-sees-q4-top-line-16-percent\" target=\"_blank\">Stryker sees Q4 top line up 16%</a> (Jan. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234701\" data-linked=\"Stryker up 2% on preliminary Q4 and full-year results that are inline with consensus\" data-tweet=\"$SYK - Stryker up 2% on preliminary Q4 and full-year results that are inline with consensus https://seekingalpha.com/news/3234701-stryker-up-2-on-preliminary-q4-and-full-year-results-are-inline-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3234701-stryker-up-2-on-preliminary-q4-and-full-year-results-are-inline-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:20 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234698\" data-ts=\"1484151454\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EROS\" target=\"_blank\">EROS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234698-eros-international-sets-50-film-slate-over-next-two-years\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Eros International sets 50-film slate over next two years</a></h4><ul>   <li>India Filmmaker Eros International (<a href='https://seekingalpha.com/symbol/EROS' title='Eros International Plc'>EROS</a> <font color='green'>+1.8%</font>), building off some fast growth on its over-the-top service, has set an ambitious slate for the next couple of years.</li>    <li>The company plans to <a href=\"https://seekingalpha.com/pr/16711216-eros-international-plc-announces-strong-film-production-slate-2017minus-2018\" target=\"_blank\">produce more than 50 films</a> across eight languages, as well as acquire content on an opportunistic basis.</li>    <li>That includes an expanded regional presence, with more than 25 releases across Bengali, Marathi, Tamil, Telugu, Malayalam and Punjabi.</li>    <li>More than 40 directors are on board and the company is partnering with Aanand L. Rai and joint project Colour Yellow, NextGen Films, and Trinity Pictures.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234698\" data-linked=\"Eros International sets 50-film slate over next two years\" data-tweet=\"$EROS - Eros International sets 50-film slate over next two years https://seekingalpha.com/news/3234698-eros-international-sets-50-film-slate-over-next-two-years?source=tweet\" data-url=\"https://seekingalpha.com/news/3234698-eros-international-sets-50-film-slate-over-next-two-years\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234690\" data-ts=\"1484150832\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKD\" target=\"_blank\">BKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234690-brookdale-up-3-on-stifel-valuation-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brookdale up 3% on Stifel valuation call</a></h4><ul><li>Brookdale Senior Living (<a href='https://seekingalpha.com/symbol/BKD' title='Brookdale Senior Living Inc.'>BKD</a> <font color='green'>+2.9%</font>) perks up on a report by Stifel Nicolaus that says the company is worth $24 (57% upside) based on a sum-of-the-parts analysis.</li><li>Other sell-side shops have yet to signal they agree. Five downgraded the stock in November after a Q3 miss. Price targets range from $12 - 16.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234690\" data-linked=\"Brookdale up 3% on Stifel valuation call\" data-tweet=\"$BKD - Brookdale up 3% on Stifel valuation call https://seekingalpha.com/news/3234690-brookdale-up-3-on-stifel-valuation-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3234690-brookdale-up-3-on-stifel-valuation-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234664\" data-ts=\"1484150421\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234664-healthcare-top-5-gainers-losers-of-11-00\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Healthcare - Top 5 Gainers / Losers as of 11:00 am</a></h4><ul>     <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/DSCI' title='Derma Sciences Inc.'>DSCI</a> <font color='green'>+39%</font>. <a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/ARWR' title='Arrowhead Pharmaceuticals'>ARWR</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/OPGN' title='OpGen'>OPGN</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/SBBP' title='Strongbridge Biopharma'>SBBP</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> SGNL <font color='red'>-38%</font>. ETRM <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/GNVC' title='GenVec, Inc.'>GNVC</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/NVDQ' title='Novadaq Technologies Inc.'>NVDQ</a> <font color='red'>-18%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234664\" data-linked=\"Healthcare - Top 5 Gainers / Losers as of 11:00 am\" data-tweet=\"$DSCI $BIOC $ARWR - Healthcare - Top 5 Gainers / Losers as of 11:00 am https://seekingalpha.com/news/3234664-healthcare-top-5-gainers-losers-of-11-00?source=tweet\" data-url=\"https://seekingalpha.com/news/3234664-healthcare-top-5-gainers-losers-of-11-00\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234685\" data-ts=\"1484149594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ASNA\" target=\"_blank\">ASNA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234685-ascena-retailminus-35-in-month-who-called-and-missed\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ascena Retail -35% in a month, here&#39;s who called it and missed it</a></h4><ul> <li>Ascena Retail (<a href='https://seekingalpha.com/symbol/ASNA' title='Ascena Retail Group Inc'>ASNA</a> <font color='red'>-3.5%</font>) is down again after cutting guidance yesterday.</li> <li>Shares of the specialty retailer are now down 35% in a month on growing concerns over sales demand, margins and border taxes.</li> <li>It's all quiet on Wall Street where 8 firms had <a href=\"https://www.marketbeat.com/stocks/NASDAQ/ASNA/\" target=\"_blank\">Hold ratings</a> on ASNA through the slide and one outlier (Piper Jaffray) stuck with a Buy rating. Meanwhile on Seeking Alpha, Christopher Davis <a href=\"https://seekingalpha.com/article/4035626-ascena-retail-group-catastrophe-looks-like\" target=\"_blank\">weighs in</a> on the Ascena \"catastrophe\" and Josh Arnold probably deserves to take a victory lap for his <a href=\"https://seekingalpha.com/article/4032967-ascena-retail-group-unmitigated-disaster\" target=\"_blank\">negative call</a> in December.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234335-holiday-sales-disappoint-ascena-retail-group\" target=\"_blank\">Holiday sales disappoint at Ascena Retail Group</a> (Jan. 10)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234356-ascena-retail-group-craters-guidance-update\" target=\"_blank\">Ascena Retail Group craters after guidance update</a> (Jan. 10)</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3234685\" data-linked=\"Ascena Retail -35% in a month, here&#39;s who called it and missed it\" data-tweet=\"$ASNA - Ascena Retail -35% in a month, here&#39;s who called it and missed it https://seekingalpha.com/news/3234685-ascena-retailminus-35-in-month-who-called-and-missed?source=tweet\" data-url=\"https://seekingalpha.com/news/3234685-ascena-retailminus-35-in-month-who-called-and-missed\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:46 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234682\" data-ts=\"1484149208\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MRK\" target=\"_blank\">MRK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234682-investors-like-upside-of-keytruda-chemo-combo-merck-up-5\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Investors like upside of Keytruda/chemo combo; Merck up 5%</a></h4><ul><li>The money flow into Merck (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color='green'>+5.1%</font>) is decidedly positive in early trading after the company announced that the FDA accepted its marketing application seeking approval for the use Keytruda (pembrolizumab), combined with chemo, to treat a type of lung cancer. The FDA's action date is May 10.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234531-fda-review-mercks-marketing-application-keytruda-combination-lung-cancer\" target=\"_blank\">FDA to review Merck's marketing application for Keytruda combination for lung cancer</a> (Jan. 10)</li></ul><div class=\"tiny-share-widget\" data-id=\"3234682\" data-linked=\"Investors like upside of Keytruda/chemo combo; Merck up 5%\" data-tweet=\"$MRK - Investors like upside of Keytruda/chemo combo; Merck up 5% https://seekingalpha.com/news/3234682-investors-like-upside-of-keytruda-chemo-combo-merck-up-5?source=tweet\" data-url=\"https://seekingalpha.com/news/3234682-investors-like-upside-of-keytruda-chemo-combo-merck-up-5\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:40 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234679\" data-ts=\"1484148672\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234679-crude-futures-give-up-gains-post-inventory-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Crude futures give up gains post inventory data</a></h4><ul><li><a href=\"http://ir.eia.gov/wpsr/wpsrsummary.pdf\" target=\"_blank\">EIA Petroleum Inventories</a>:</li><li>Crude <strong>+4.1</strong><strong>M</strong> barrels vs. +1.2M consensus, -7.1M last week.</li><li>Gasoline <strong>+5</strong><strong>M</strong> barrels vs. +1.7M consensus, +8.3M last week.</li><li>Distillates <strong>+8.4</strong><strong>M</strong> barrels vs. +0.9M consensus, +10M last week.</li><li>Futures&nbsp;<font color='green'>+0.18%</font>&nbsp;to $50.92.</li><li>ETFs:<a href='https://seekingalpha.com/symbol/USO' title='The United States Oil ETF, LP'>USO</a>,                      <a href='https://seekingalpha.com/symbol/OIL' title='iPath S&P Crude Oil Total Return Index ETN'>OIL</a>, <a href='https://seekingalpha.com/symbol/UCO' title='ProShares Ultra Bloomberg Crude Oil ETF'>UCO</a>, <a href='https://seekingalpha.com/symbol/SCO' title='ProShares UltraShort Bloomberg Crude Oil ETF'>SCO</a>, <a href='https://seekingalpha.com/symbol/BNO' title='The United States Brent Oil ETF, LP'>BNO</a>, <a href='https://seekingalpha.com/symbol/DTO' title='DB Crude Oil Double Short ETN'>DTO</a>,   <a href='https://seekingalpha.com/symbol/DBO' title='PowerShares DB Oil ETF'>DBO</a>,           <a href='https://seekingalpha.com/symbol/UWT' title='VelocityShares 3X Long Crude ETN'>UWT</a>,          <a href='https://seekingalpha.com/symbol/USL' title='The United States 12 Month Oil ETF, LP'>USL</a>, <a href='https://seekingalpha.com/symbol/DWT' title='VelocityShares 3x Inverse Crude Oil ETN'>DWT</a>, <a href='https://seekingalpha.com/symbol/DNO' title='The United States Short Oil ETF, LP'>DNO</a>,   <a href='https://seekingalpha.com/symbol/SZO' title='DB Crude Oil Short ETN'>SZO</a>,  <a href='https://seekingalpha.com/symbol/OLO' title='DB Crude Oil Long ETN'>OLO</a>,          <a href='https://seekingalpha.com/symbol/OLEM' title='iPath Pure Beta Crude Oil ETN'>OLEM</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234679\" data-linked=\"Crude futures give up gains post inventory data\" data-tweet=\"$USO $OIL $UCO - Crude futures give up gains post inventory data https://seekingalpha.com/news/3234679-crude-futures-give-up-gains-post-inventory-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3234679-crude-futures-give-up-gains-post-inventory-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234678\" data-ts=\"1484148578\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WDAY\" target=\"_blank\">WDAY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234678-workdayplus-7_2-william-blair-indicates-contract-company-employing-2m\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Workday +7.2%; William Blair indicates contract with company employing 2M+</a></h4><ul><li>Though unaware of the exact size of said deal, <a href=\"https://www.benzinga.com/analyst-ratings/analyst-color/17/01/8894010/workdays-quarter-might-be-turning-out-better-than-expect\" target=\"_blank\">analyst Justin Firby</a> notes the company would be the largest Workday has to this point signed with, five times larger specifically on a headcount premise than any existing customer. Workday is claimed to have been in competition for the contract with SAP.</li><li>While difficult to determine precisely given lack of knowledge on terms, notes potential for a deal at such scale to add $30M+ in annual subscription revenue.</li><li>Further checks also signal arrangements closed with various other operations, particularly with a real estate firm employing 70K+ and a pharmaceutical firm employing 50K+.</li><li>Reissues Workday (NYSE:<a href='https://seekingalpha.com/symbol/WDAY' title='Workday'>WDAY</a>) at Outperform.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234678\" data-linked=\"Workday +7.2%; William Blair indicates contract with company employing 2M+\" data-tweet=\"$WDAY - Workday +7.2%; William Blair indicates contract with company employing 2M+ https://seekingalpha.com/news/3234678-workdayplus-7_2-william-blair-indicates-contract-company-employing-2m?source=tweet\" data-url=\"https://seekingalpha.com/news/3234678-workdayplus-7_2-william-blair-indicates-contract-company-employing-2m\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>25&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234677\" data-ts=\"1484148562\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DRYS\" target=\"_blank\">DRYS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234677-sinking-feeling-for-dryships\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sinking feeling for DryShips</a></h4><ul><li>DryShips (<a href='https://seekingalpha.com/symbol/DRYS' title='DryShips Inc.'>DRYS</a> <font color='red'>-8.4%</font>) retreats again as the shipping stock continues its dismal run.</li><li>If today's decline holds up, it would the 13th straight down day for the stock.</li><li>SA contributor Henrik Allen was out with a <a href=\"https://seekingalpha.com/article/4032971-dryships-continues-sail-economou-class-closer-look-latest-toxic-financing-agreement\" target=\"_blank\">short call</a>&nbsp;on DRYS&nbsp;right in front of the tailspin.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234677\" data-linked=\"Sinking feeling for DryShips\" data-tweet=\"$DRYS - Sinking feeling for DryShips https://seekingalpha.com/news/3234677-sinking-feeling-for-dryships?source=tweet\" data-url=\"https://seekingalpha.com/news/3234677-sinking-feeling-for-dryships\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:29 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234676\" data-ts=\"1484148306\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AAP\" target=\"_blank\">AAP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234676-advance-auto-parts-pushes-higher-after-cleveland-research-nod\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Advance Auto Parts pushes higher after Cleveland Research nod</a></h4><ul> <li>Advance Auto Parts (<a href='https://seekingalpha.com/symbol/AAP' title='Advance Auto Parts, Inc.'>AAP</a> <font color='green'>+1.5%</font>) rallies after Cleveland Research bumps its rating to Buy from Neutral.</li> <li>The investment firm sees upside off of AAP's comparable sales improvement and margin recovery.</li> <li>What to watch:&nbsp;There's been some nervous trading around the auto retailer sector on concerns that a border tax could cut directly into margins. Many auto parts are sourced from Asia.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3234676\" data-linked=\"Advance Auto Parts pushes higher after Cleveland Research nod\" data-tweet=\"$AAP - Advance Auto Parts pushes higher after Cleveland Research nod https://seekingalpha.com/news/3234676-advance-auto-parts-pushes-higher-after-cleveland-research-nod?source=tweet\" data-url=\"https://seekingalpha.com/news/3234676-advance-auto-parts-pushes-higher-after-cleveland-research-nod\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:25 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234672\" data-ts=\"1484147717\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/WWR\" target=\"_blank\">WWR</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234672-uranium-producers-surge-top-supplier-plans-production-cut\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Uranium producers surge as top supplier plans production cut</a></h4><ul>     <li>Shares of uranium producers shoot higher for a second straight day after spot prices for the commodity <a href=\"http://www.wsj.com/articles/uranium-price-jumps-as-top-supplier-pulls-back-1484128198\" target=\"_blank\">surge 10%</a> after Kazakhstan's state nuclear-fuel company said the country would not produce as much uranium as planned this year.</li>     <li>Analysts say the announcement from Kazakhstan, the world&rsquo;s biggest producer, may mark an <a href=\"https://www.bloomberg.com/news/articles/2017-01-11/uranium-surges-10-as-top-producer-signals-output-cut-amid-glut\" target=\"_blank\">inflection point</a> for the market and could lead to higher prices.</li><li>In today's trade: URRE <font color='green'>+32.4%</font>, <a href='https://seekingalpha.com/symbol/UEC' title='Uranium Energy Corp'>UEC</a> <font color='green'>+14.8%</font>, <a href='https://seekingalpha.com/symbol/DNN' title='Denison Mines Corp'>DNN</a> <font color='green'>+8.7%</font>, <a href='https://seekingalpha.com/symbol/URG' title='Ur-Energy Inc.'>URG</a> <font color='green'>+6.8%</font>, <a href='https://seekingalpha.com/symbol/UUUU' title='Energy Fuels Inc'>UUUU</a> <font color='green'>+5.5%</font>, <a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='green'>+4.1%</font>, after big gains yesterday.</li>     <li>Uranium prices have largely been in free fall since the 2011 disaster at Japan's Fukushima Daiichi nuclear power plant, sliding to a 12-year low of $18/lb. in December, but prices yesterday jumped above $24 for the first time since September.</li><li>ETF: <a href='https://seekingalpha.com/symbol/URA' title='Global X Uranium ETF'>URA</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234672\" data-linked=\"Uranium producers surge as top supplier plans production cut\" data-tweet=\"$WWR $WWR $UEC - Uranium producers surge as top supplier plans production cut https://seekingalpha.com/news/3234672-uranium-producers-surge-top-supplier-plans-production-cut?source=tweet\" data-url=\"https://seekingalpha.com/news/3234672-uranium-producers-surge-top-supplier-plans-production-cut\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>65&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234670\" data-ts=\"1484147594\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HEB\" target=\"_blank\">HEB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234670-european-early-access-program-for-hemispherx-bios-rintatolimod-expanded-to-pancreatic-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European early access program for Hemispherx Bio&#39;s rintatolimod expanded to pancreatic cancer; shares ahead 2%</a></h4><ul><li>Thinly traded nano cap Hemispherx Biopharma (<a href='https://seekingalpha.com/symbol/HEB' title='Hemispherx Biopharma, Inc'>HEB</a> <font color='green'>+2.4%</font>) perks up on light volume on the heels of its <a href=\"https://seekingalpha.com/pr/16711148-hemispherx-biopharma-announces-extension-rintatolimod-european-early-access-program-eap\" target=\"_blank\">announcement </a>that the European Early Access Program &#40;EAP&#41; for rintatolimod has been extended to pancreatic cancer patients, beginning in the Netherlands. MyTomorrows, the company's exclusive service provider in Europe and Turkey, will manage the EAP activities related to the extension as well as the existing activities related to early access in chronic fatigue syndrome patients.</li><li>Rintatolimod, branded as <a href=\"http://www.hemispherx.net/product-candidates-overview.php\" target=\"_blank\">Ampligen&nbsp;</a>in the U.S.,&nbsp;is an experimental therapeutic in a new class of specifically-configured RNA compounds for the treatment of diseases with immunologic defects and/or viral causation.&nbsp;It's been \"experimental\" for 25 years so investors should take note.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234670\" data-linked=\"European early access program for Hemispherx Bio&#39;s rintatolimod expanded to pancreatic cancer; shares ahead 2%\" data-tweet=\"$HEB $AIM - European early access program for Hemispherx Bio&#39;s rintatolimod expanded to pancreatic cancer; shares ahead 2% https://seekingalpha.com/news/3234670-european-early-access-program-for-hemispherx-bios-rintatolimod-expanded-to-pancreatic-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3234670-european-early-access-program-for-hemispherx-bios-rintatolimod-expanded-to-pancreatic-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234667\" data-ts=\"1484146972\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BRG\" target=\"_blank\">BRG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234667-bluerock-residential-down-5_1-after-50m-equity-raise\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bluerock Residential down 5.1% after $50M equity raise</a></h4><ul><li>The <a href=\"https://seekingalpha.com/pr/16711410-bluerock-residential-growth-reit-brg-prices-class-common-stock-offering\" target=\"_blank\">company sold 4M shares</a> for $13.15 each for total net proceeds of about $49.77M. The underwriters have an option to buy another 600K shares at that price.</li><li><a href='https://seekingalpha.com/symbol/BRG' title='Bluerock Residential Growth REIT, Inc.'>BRG</a><font color='red'> -5.1%</font>&nbsp;to $13.14.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234667\" data-linked=\"Bluerock Residential down 5.1% after $50M equity raise\" data-tweet=\"$BRG - Bluerock Residential down 5.1% after $50M equity raise https://seekingalpha.com/news/3234667-bluerock-residential-down-5_1-after-50m-equity-raise?source=tweet\" data-url=\"https://seekingalpha.com/news/3234667-bluerock-residential-down-5_1-after-50m-equity-raise\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:02 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234647\" data-ts=\"1484144282\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVU\" target=\"_blank\">SVU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234647-margins-disappoint-supervalu\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Margins disappoint at Supervalu</a></h4><ul> <li>Supervalu (NYSE:<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a>) is lower following a disappointing report on margin rates with its Q4 report.</li> <li>RBC analyst William Kirk notes that retail adjusted EBIT came in at $2M vs. the firm's estimate of $5M.</li> <li>Supervalu has a conference call scheduled for 9:00 AM Eastern during which a guidance update is expected.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234577-supervalu-misses-0_08-misses-revenue\" target=\"_blank\">SUPERVALU misses by $0.08, misses on revenue</a> (Jan. 11)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3234585-supervalus-fq3\" target=\"_blank\">More on Supervalu's FQ3</a> (Jan. 11)</li> <li>SVU <font color='red'>-3.55%</font> premarket to $4.62.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3234647\" data-linked=\"Margins disappoint at Supervalu\" data-tweet=\"$SVU - Margins disappoint at Supervalu https://seekingalpha.com/news/3234647-margins-disappoint-supervalu?source=tweet\" data-url=\"https://seekingalpha.com/news/3234647-margins-disappoint-supervalu\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:18 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234646\" data-ts=\"1484144027\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234646-premarket-gainers-losers-of-9-10\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket Gainers / Losers as of 9:10 am</a></h4><ul> <li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/BIOC' title='Biocept, Inc.'>BIOC</a> <font color='green'>+45%</font>. <a href='https://seekingalpha.com/symbol/DSCI' title='Derma Sciences Inc.'>DSCI</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/ENPH' title='Enphase Energy Inc.'>ENPH</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a> <font color='green'>+12%</font>. <a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a> <font color='green'>+9%</font>. <a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen'>AKAO</a> <font color='green'>+8%</font>.</li> <li><b>Losers:</b> ETRM <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/NVDQ' title='Novadaq Technologies Inc.'>NVDQ</a> <font color='red'>-18%</font>. <a href='https://seekingalpha.com/symbol/TRCO' title='Tribune Media Company'>TRCO</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/IMUC' title='ImmunoCellular Therapeutics, Ltd.'>OTCPK:IMUC</a> <font color='red'>-14%</font>. <a href='https://seekingalpha.com/symbol/GNVC' title='GenVec, Inc.'>GNVC</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/XGTI' title='xG Technology, Inc.'>XGTI</a> <font color='red'>-9%</font>. <a href='https://seekingalpha.com/symbol/ROKA' title='Roka Bioscience'>ROKA</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/BRG' title='Bluerock Residential Growth REIT, Inc.'>BRG</a> <font color='red'>-5%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3234646\" data-linked=\"Premarket Gainers / Losers as of 9:10 am\" data-tweet=\"$BIOC $DSCI $ENPH - Premarket Gainers / Losers as of 9:10 am https://seekingalpha.com/news/3234646-premarket-gainers-losers-of-9-10?source=tweet\" data-url=\"https://seekingalpha.com/news/3234646-premarket-gainers-losers-of-9-10\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234644\" data-ts=\"1484143743\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RAD\" target=\"_blank\">RAD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234644-ny-post-rite-aid-walgreens-ftc-approval-expected-day\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NY Post: Rite Aid-Walgreens FTC approval expected any day</a></h4><ul> <li>Rite Aid (NYSE:<a href='https://seekingalpha.com/symbol/RAD' title='Rite Aid Corporation'>RAD</a>) shoots higher in premarket trading after New York Post <a href=\"http://nypost.com/2017/01/10/walgreens-rite-aid-merger-expected-any-day-now/\" target=\"_blank\">reports</a> that FTC approval on the merger with Walgreens Boots Alliance (NASDAQ:<a href='https://seekingalpha.com/symbol/WBA' title='Walgreens Boots Alliance, Inc.'>WBA</a>) is only days away.</li> <li>Sources indicate FTC Commissioner Maureen Ohlausen isn't going to block the deal.</li> <li>RAD <font color='green'>+3.85%</font> premarket to $8.64. WBA <font color='green'>+0.77%</font> to $83.31.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3234644\" data-linked=\"NY Post: Rite Aid-Walgreens FTC approval expected any day\" data-tweet=\"$RAD $RAD $WBA - NY Post: Rite Aid-Walgreens FTC approval expected any day https://seekingalpha.com/news/3234644-ny-post-rite-aid-walgreens-ftc-approval-expected-day?source=tweet\" data-url=\"https://seekingalpha.com/news/3234644-ny-post-rite-aid-walgreens-ftc-approval-expected-day\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:09 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>59&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234643\" data-ts=\"1484143661\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKAO\" target=\"_blank\">AKAO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234643-achaogen-up-8-premarket-on-baker-bros-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Achaogen up 8% premarket on Baker Bros. stake</a></h4><ul><li>Achaogen (NASDAQ:<a href='https://seekingalpha.com/symbol/AKAO' title='Achaogen'>AKAO</a>) is up&nbsp;<font color='green'>8%</font>&nbsp;premarket on average volume in apparent response to a <a href=\"https://www.sec.gov/Archives/edgar/data/1263508/000114420417001603/v456676_sc13g.htm\" target=\"_blank\">13D filing</a> from hedge fund investor Baker Brothers that reported a position of ~4.6M shares.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234643\" data-linked=\"Achaogen up 8% premarket on Baker Bros. stake\" data-tweet=\"$AKAO - Achaogen up 8% premarket on Baker Bros. stake https://seekingalpha.com/news/3234643-achaogen-up-8-premarket-on-baker-bros-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3234643-achaogen-up-8-premarket-on-baker-bros-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:07 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234640\" data-ts=\"1484143340\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KERX\" target=\"_blank\">KERX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234640-keryx-bio-up-5-premarket-on-citi-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Keryx Bio up 5% premarket on Citi upgrade</a></h4><ul><li>Keryx Biopharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/KERX' title='Keryx Biopharmaceuticals, Inc.'>KERX</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket, albeit on only 2,600 shares, on the heels of an upgrade by Citigroup to Neutral from Sell. Analyst Yigal Nochomovitz also raised the price target to $6.50 (5% upside from yesterday's close) from $4.00.</li><li>Auryxia (ferric citrate) relaunch data are above expectations. Q4 sales should be ~$9.5M while the full-year tally should be ~$31.9M.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234640\" data-linked=\"Keryx Bio up 5% premarket on Citi upgrade\" data-tweet=\"$KERX - Keryx Bio up 5% premarket on Citi upgrade https://seekingalpha.com/news/3234640-keryx-bio-up-5-premarket-on-citi-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3234640-keryx-bio-up-5-premarket-on-citi-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:02 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234634\" data-ts=\"1484142788\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HIMX\" target=\"_blank\">HIMX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234634-himax-technologies-downgraded-to-neutral-roth-capital\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Himax Technologies downgraded to Neutral at Roth Capital</a></h4><ul><li><a href=\"http://www.streetinsider.com/Downgrades/Roth+Capital+Downgrades+Himax+Technologies+%28HIMX%29+to+Neutral/12415686.html\" target=\"_blank\">From Buy</a>, the firm follows similar ratings movements already issued this week at <a href=\"https://seekingalpha.com/news/3234107-himax-technologies-downgraded-northland-capital-markets\" target=\"_blank\">Northland Capital Markets</a> and <a href=\"https://seekingalpha.com/news/3234476-craig-hallum-downgrades-himax-technologies-hold\" target=\"_blank\">Craig-Hallum</a>.</li><li>Himax Technologies (NASDAQ:<a href='https://seekingalpha.com/symbol/HIMX' title='Himax Technologies, Inc.'>HIMX</a>)&nbsp;<font color='red'>-2.97%</font>&nbsp;pre-market.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234634\" data-linked=\"Himax Technologies downgraded to Neutral at Roth Capital\" data-tweet=\"$HIMX - Himax Technologies downgraded to Neutral at Roth Capital https://seekingalpha.com/news/3234634-himax-technologies-downgraded-to-neutral-roth-capital?source=tweet\" data-url=\"https://seekingalpha.com/news/3234634-himax-technologies-downgraded-to-neutral-roth-capital\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>58&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234633\" data-ts=\"1484142743\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PACB\" target=\"_blank\">PACB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234633-pacific-bio-poised-to-continue-up-move-shares-ahead-5-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Pacific Bio poised to continue up move, shares ahead 5% premarket</a></h4><ul><li>Pacific Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California'>PACB</a>) is up&nbsp;<font color='green'>5%</font>&nbsp;premarket on light volume. Shares have rallied almost 32% this year after plummeting in mid-December after Roche exited its development deal related to SMRT diagnostics.</li><li>On Monday, the company <a href=\"https://seekingalpha.com/pr/16708844-update-pacific-biosciences-improves-key-applications-sequel-system-new-chemistry-software\" target=\"_blank\">announced </a>new software updates to its Sequel System that it says improves applications like structural variant detection and targeted sequencing. The updates will be available on January 23.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234633\" data-linked=\"Pacific Bio poised to continue up move, shares ahead 5% premarket\" data-tweet=\"$PACB - Pacific Bio poised to continue up move, shares ahead 5% premarket https://seekingalpha.com/news/3234633-pacific-bio-poised-to-continue-up-move-shares-ahead-5-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3234633-pacific-bio-poised-to-continue-up-move-shares-ahead-5-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234622\" data-ts=\"1484141355\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGTX\" target=\"_blank\">TGTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234622-tg-therapeutics-shares-up-8-on-completing-enrollment-and-b-cell-depletion-data-from-part-1-of\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">TG Therapeutics shares up 8% on completing enrollment and B-cell depletion data from part 1 of ongoing phase 2 RMS study</a></h4><ul><li>TG Therapeutics (NASDAQ:<a href='https://seekingalpha.com/symbol/TGTX' title='TG Therapeutics, Inc.'>TGTX</a>) <a href=\"https://seekingalpha.com/pr/16711002-tg-therapeutics-announces-completion-enrollment-b-cell-depletion-data-part-1-ongoing-phase-2\" target=\"_blank\">announces</a> the completion of enrollment into Part 1 of its ongoing Phase 2 study of TG-1101 (ublituximab), the Company's novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis &#40;RMS&#41;.</li><li>The primary objective of the study is to assess the safety and tolerability of TG-1101 in patients with RMS as well as to determine the optimal dosing regimen for by examining the level of B-cell depletion and the tolerability of accelerated infusion times.</li><li>Established MS clinical efficacy endpoints are also being evaluated, which require longer-term follow-up and are anticipated to be reported on later this year or next year at a medical conference.</li>  <li>The median B-cell depletion for all patients in Part 1 was 99% and TG-1101 was well-tolerated with no grade 3/4 adverse events reported, including in patients receiving the one-hour infusion at the target Phase 3 dose and infusion rate.</li><li>The Phase 3 program will initiate in H1.</li><li>Shares are up&nbsp;<font color='green'>8%</font>&nbsp;premarket on light volume.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3234622\" data-linked=\"TG Therapeutics shares up 8% on completing enrollment and B-cell depletion data from part 1 of ongoing phase 2 RMS study\" data-tweet=\"$TGTX - TG Therapeutics shares up 8% on completing enrollment and B-cell depletion data from part 1 of ongoing phase 2 RMS study https://seekingalpha.com/news/3234622-tg-therapeutics-shares-up-8-on-completing-enrollment-and-b-cell-depletion-data-from-part-1-of?source=tweet\" data-url=\"https://seekingalpha.com/news/3234622-tg-therapeutics-shares-up-8-on-completing-enrollment-and-b-cell-depletion-data-from-part-1-of\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:29 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234616\" data-ts=\"1484140209\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SGMO\" target=\"_blank\">SGMO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234616-sangamos-sbminus-318-orphan-drug-for-mps-i-shares-up-7-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sangamo&#39;s SB-318 an Orphan Drug for MPS I; shares up 7% premarket</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/16711000-sangamo-therapeutics-receives-orphan-drug-designation-fda-sbminus-318-genome-editing\" target=\"_blank\">designates</a> Sangamo Therapeutics' (NASDAQ:<a href='https://seekingalpha.com/symbol/SGMO' title='Sangamo Therapeutics, Inc.'>SGMO</a>) SB-318 an Orphan Drug for the treatment of Mucopolysaccharidosis Type I (MPS I), a rare inherited lysosomal storage disorder caused by mutations in the IDUA gene.</li><li>Phase 1/2-stage SB-318 is a zinc finger nuclease &#40;ZFN&#41;&nbsp;gene editing therapy designed to provided stable continuous production of the IDUA enzyme.</li><li>Among the benefits of Orphan Drug status is a seven-year period of market exclusivity in the U.S. for the indication, if approved.</li><li>Shares are up&nbsp;<font color='green'>7%&nbsp;</font>premarket on light volume.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234616\" data-linked=\"Sangamo&#39;s SB-318 an Orphan Drug for MPS I; shares up 7% premarket\" data-tweet=\"$SGMO - Sangamo&#39;s SB-318 an Orphan Drug for MPS I; shares up 7% premarket https://seekingalpha.com/news/3234616-sangamos-sbminus-318-orphan-drug-for-mps-i-shares-up-7-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3234616-sangamos-sbminus-318-orphan-drug-for-mps-i-shares-up-7-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:10 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234615\" data-ts=\"1484140049\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BKD\" target=\"_blank\">BKD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234615-brookdale-senior-sale-story-legs-shares-up-another-2-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Brookdale Senior sale story has legs; shares up another 2% premarket</a></h4><ul><li>Brookdale Senior Living (NYSE:<a href='https://seekingalpha.com/symbol/BKD' title='Brookdale Senior Living Inc.'>BKD</a>)&nbsp;<font color='green'>gained 15.2%</font>&nbsp;to close at $14.80 yesterday on word it was engaged in sale discussions.</li><li>Stifel's Chad Vanacore says it could be worth $23 in a sale, and upgrades to Buy.</li><li>RBC says $21.</li><li>Activist Land &amp; Buildings - which has pushed for Brookdale to sell or spin off its real estate - says the company's property holdings alone could be worth $7B, or well more than double the current market cap.</li><li>Brookdale was about a $40 stock two years ago.</li><li>Shares&nbsp;<font color='green'>+2.2%</font>&nbsp;premarket to $15.13.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234615\" data-linked=\"Brookdale Senior sale story has legs; shares up another 2% premarket\" data-tweet=\"$BKD - Brookdale Senior sale story has legs; shares up another 2% premarket https://seekingalpha.com/news/3234615-brookdale-senior-sale-story-legs-shares-up-another-2-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3234615-brookdale-senior-sale-story-legs-shares-up-another-2-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:07 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234608\" data-ts=\"1484139224\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADM\" target=\"_blank\">ADM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234608-admminus-5_6-premarket-china-hikes-duties-on-u-s-ethanol-product\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">ADM -5.6% premarket as China hikes duties on U.S. ethanol by-product</a></h4><ul>     <li>Archer Daniels Midland (NYSE:<a href='https://seekingalpha.com/symbol/ADM' title='Archer Daniels Midland Co.'>ADM</a>) <font color='red'>-5.6%</font> premarket as <a href=\"http://www.reuters.com/article/us-china-grains-usa-idUSKBN14V09S\" target=\"_blank\">China sharply increases punitive tariffs</a> on imports of distillers dried grains, a by-product of corn ethanol that is used as animal feed, from levels first proposed last year.</li>     <li>China's Commerce Ministry, responding to complaints from the country's fledgling ethanol industry, ruled that anti-dumping duties will range from 42.2% to 53.7%, up from 33.8% in its preliminary decision in September.</li><li>The decision is considered a blow to the larger U.S.  ethanol industry, particularly ethanol trader ADM, producer Valero Energy (NYSE:<a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a>) and grains  handler Andersons (NASDAQ:<a href='https://seekingalpha.com/symbol/ANDE' title='The Andersons, Inc.'>ANDE</a>).</li>     <li>The decision could escalate a trade dispute between the U.S. and China, and Pres.-elect Trump has threatened to impose punitive tariffs on certain Chinese goods coming into the U.S..</li></ul><div class=\"tiny-share-widget\" data-id=\"3234608\" data-linked=\"ADM -5.6% premarket as China hikes duties on U.S. ethanol by-product\" data-tweet=\"$ADM $ADM $VLO - ADM -5.6% premarket as China hikes duties on U.S. ethanol by-product https://seekingalpha.com/news/3234608-admminus-5_6-premarket-china-hikes-duties-on-u-s-ethanol-product?source=tweet\" data-url=\"https://seekingalpha.com/news/3234608-admminus-5_6-premarket-china-hikes-duties-on-u-s-ethanol-product\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:53 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>33&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234593\" data-ts=\"1484136848\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SIG\" target=\"_blank\">SIG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234593-signet-jewelers-updates-on-holiday-season-sales\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Signet Jewelers updates on holiday season sales</a></h4><ul> <li>Signet Jewelers &nbsp;(NYSE:<a href='https://seekingalpha.com/symbol/SIG' title='Signet Jewelers Limited'>SIG</a>) reports same store sales decreased 4.6% for the nine-week holiday period.</li><li>Total sales fell 5.1% or -3.3% on a constant curreny basis</li><li>The company says it's&nbsp;maintaining the low-end of its earnings guidance based off the performance.</li><li>Q4 guidance: Same-store sales -4.8% to -4.3%, EPS $4.00-$4.05.</li><li>FY guidance: Same-store sales -2.5% to -2.0%, EPS $7.38-$7.43.</li><li>SIG&nbsp;<font color='red'>-4.49%</font>&nbsp;premarket to $83.53.</li><li>Source: <a href=\"https://seekingalpha.com/pr/16710933-signet-jewelers-reports-holiday-season-sales\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3234593\" data-linked=\"Signet Jewelers updates on holiday season sales\" data-tweet=\"$SIG - Signet Jewelers updates on holiday season sales https://seekingalpha.com/news/3234593-signet-jewelers-updates-on-holiday-season-sales?source=tweet\" data-url=\"https://seekingalpha.com/news/3234593-signet-jewelers-updates-on-holiday-season-sales\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234584\" data-ts=\"1484136213\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IART\" target=\"_blank\">IART</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234584-integra-lifesciences-buys-derma-sciences-for-7-share\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Integra LifeSciences buys Derma Sciences for $7/share</a></h4><ul><li>Integra LifeSciences (NASDAQ:<a href='https://seekingalpha.com/symbol/IART' title='Integra LifeSciences Holdings Corporation'>IART</a>) <a href=\"https://seekingalpha.com/pr/16710787-integra-lifesciences-acquire-derma-sciences-inc-announces-preliminary-fourth-quarter-full\" target=\"_blank\">agrees to acquire</a> Derma Sciences (NASDAQ:<a href='https://seekingalpha.com/symbol/DSCI' title='Derma Sciences Inc.'>DSCI</a>) for $7 per share in cash. Integra will also purchase all the outstanding shares of Derma preferred stock for an amount equal to its liquidation preference per share. The transaction should close by the end of the quarter.</li><li><a href=\"http://www.dermasciences.com/about\" target=\"_blank\">Derma </a>is a tissue regeneration firm that specializes in wound care products. <a href=\"http://www.integralife.com/index.aspx\" target=\"_blank\">Integra</a> develops a range of medical products and devices used by surgeons, including wound care products.</li><li>Derma closed yesterday at $5.</li><li>On a preliminary basis, Integra expects Q4 and full-year revenues to come in at $256M and $992M, respectively, representing organic growth of 7% and 9%, respectively. Full-year GAAP and non-GAAP EPS should be at or above the mid-range of $0.91 - 0.94 and $1.73 - 1.77, respectively. Cash flow ops for the year should be more than $145M.</li><li><strong>2017 guidance</strong>: non-GAAP EPS: $1.91 - 1.97, exclusive of Derma. Assuming a late Q1 close, Derma should add ~$65M in revenues and be dilutive ($0.03) per share (non-GAAP). Earnings are expected to be accretive in 2018. The acquisition should meet Integra's internal invested capital hurdle rate by the end of the third year.</li><li>Integra will host a conference call this morning at 9:00 am ET to discuss the Derma deal.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234584\" data-linked=\"Integra LifeSciences buys Derma Sciences for $7/share\" data-tweet=\"$IART $IART $DSCI - Integra LifeSciences buys Derma Sciences for $7/share https://seekingalpha.com/news/3234584-integra-lifesciences-buys-derma-sciences-for-7-share?source=tweet\" data-url=\"https://seekingalpha.com/news/3234584-integra-lifesciences-buys-derma-sciences-for-7-share\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:03 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234585\" data-ts=\"1484136088\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SVU\" target=\"_blank\">SVU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234585-on-supervalus-fq3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on Supervalu&#39;s FQ3</a></h4><ul>     <li>Supervalu (NYSE:<a href='https://seekingalpha.com/symbol/SVU' title='SUPERVALU Inc.'>SVU</a>) reports Wholesale net sales grew 0.2% to $1.91B primarily due to sales to new customers and increased sales to new stores operated by existing customers.</li>     <li>Retail net sales decreased 3.4% to $1.06B and identical store sales down 5.7%.</li>     <li>Gross margin rate declined 70 bps at 13.6%&nbsp;due to lower TSA fees and higher employee costs.</li>     <li>Adjusted SG&amp;A expense rate improved 30 bps to 11.6% primarily due to lower pension expense.</li>     <li>Operating margin rate dropped 210 bps to 0.1%.</li>     <li><a href=\"https://seekingalpha.com/pr/16710918-supervalu-reports-third-quarter-fiscal-2017-results\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3234585\" data-linked=\"More on Supervalu&#39;s FQ3\" data-tweet=\"$SVU - More on Supervalu&#39;s FQ3 https://seekingalpha.com/news/3234585-on-supervalus-fq3?source=tweet\" data-url=\"https://seekingalpha.com/news/3234585-on-supervalus-fq3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  7:01 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3234579\" data-ts=\"1484134949\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AKER\" target=\"_blank\">AKER</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3234579-akers-prices-equity-offering\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Akers prices equity offering</a></h4><ul><li>Akers Biosciences (NASDAQ:<a href='https://seekingalpha.com/symbol/AKER' title='Akers Biosciences Inc.'>AKER</a>) <a href=\"https://seekingalpha.com/pr/16709218-akers-biosciences-announces-pricing-public-offering-1667-000-shares-833500-warrants\" target=\"_blank\">prices </a>its public offering of 1.667M shares of common stock at $1.20 and 833,500 five-year warrants to purchase common shares at $1.50. Gross proceeds should be ~$2M. Closing date is January 13.</li><li>Net proceeds will fund working capital, the acceleration of growth in the U.S. and International markets and the launch of new diagnostic products.</li></ul><div class=\"tiny-share-widget\" data-id=\"3234579\" data-linked=\"Akers prices equity offering\" data-tweet=\"$AKER - Akers prices equity offering https://seekingalpha.com/news/3234579-akers-prices-equity-offering?source=tweet\" data-url=\"https://seekingalpha.com/news/3234579-akers-prices-equity-offering\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  6:42 AM </div></div></li>","count":63,"message":null,"success":true,"today":{"start":1576990800,"end":1577077199,"str":"Sunday, December 22, 2019"},"yesterday":{"start":1576904400,"end":1576990799}}